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ABSTRACT 
 Alzheimer’s disease (AD) is a neurodegenerative disease in which the 
brain progressively deteriorates resulting in cognitive decline, language 
impairment, diminished spatial awareness, memory loss and ultimately, death. 
AD is the most prevalent neurodegenerative disease and the number of people 
afflicted by AD is expected to more than double in the next 30 years. AD is 
characterized in part by the formation of amyloid plaque deposits in the brain. It is 
known that these plaques are composed of the peptide Aβ, which aggregates as 
a function of age and is produced locally within the brain by cleavage of the 
Amyloid precursor protein (APP). It is now recognized that type 2 diabetes is a 
risk factor for the development AD and the AD brain has impaired insulin 
signaling. Transgenic mice lacking the APP gene show broad changes in 
metabolism, suggesting APP may play an important in regulating metabolic 
homeostasis. This dissertation consists of two central studies aimed at 
understanding the relationship between APP and insulin signaling. The first aim 
is to examine the role APP plays in plaque formation within the pancreas and to 
understand APP’s contribution to endocrine pancreas physiology. The second 
aim is to examine the role APP plays in the regulation of the Insulin Degrading 
Enzyme (IDE).
xiv 
 In the first study, APP is found to be present in the pancreas and 
overexpressed within the insulin producing β cells in the APP/PS1 mouse model 
of AD. APP presence and overexpression does not result in the formation of the 
Aβ peptide or plaques, but instead APP is processed through α-secretase 
pathway to yield sAPPα. In primary cultures of pancreatic islets, increased APP 
expression results in increased insulin secretion. sAPPα was detected in the cell 
conditioned media of pancreatic islet primary cell cultures. Application of 
recombinant sAPPα to both human and mouse pancreatic islet cultures 
potentiates glucose stimulated insulin secretion. This effect is observed when 
sAPPα was applied to the Min6 pancreatic β cell line. The BACE2 enzyme, an 
APP cleaving α-secretase enzyme, localizes to pancreatic α cells.  Additionally, 
increased protein levels of IDE are observed in both pancreatic tissue lysate and 
primary islet cultures of mice lacking the APP gene (APP-/-).  
 In the second study, we found IDE protein is found be increased in 
numerous tissues including muscle, liver and brain from the APP-/- mouse 
compared to wild type (WT) controls. IDE mRNA levels are also found to be 
increased in APP-/- animal brain tissue. IDE protein is ubiquitous in the brain and 
is detectable in neuron, astrocyte and microglia primary cell cultures. APP-/- 
primary cultures of these cell types shows increased protein levels of IDE. siRNA 
knockdown of APP is sufficient to increase IDE protein in a cell line. IDE activity 
is found to be increased in APP-/- tissues. APP-/- brain tissue shows diminished 
levels of insulin signaling and reduced insulin content. Synaptosomes stimulated 
xv 
acutely with insulin from APP-/- animals show diminished insulin signaling 
compared to WT synaptosomes.
 1 
CHAPTER I 
INTRODUCTION 
Preface 
 The topic of this dissertation is focused on the role of the amyloid 
precursor protein (APP) and its contribution to insulin homeostasis. APP is 
established to play a central role in the pathology of Alzheimer’s Disease. Insulin 
signaling and metabolic homeostasis are important factors in influencing the 
progression of the disease. Elucidating the precise physiologic role APP plays in 
metabolic function and insulin signaling is essential for understanding the 
pathophysiology of this debilitating neurodegenerative disease. 
 For this dissertation, two separate studies were conducted involving the 
role of Amyloid precursor protein and its role in the production, secretion and 
clearance of the insulin peptide. The first study examines the amyloid precursor 
protein in the pancreas and tests the hypothesis that Alzheimer’s disease-like 
peptide plaques can form in the insulin producing β-cells to cause local cell 
death, insulin insufficiency and glucose intolerance. The second study builds off 
of findings in the first and examines the role of amyloid precursor protein in both 
the central nervous system and peripheral organs to test the hypothesis that APP 
acts as a negative regulator of the Insulin Degrading Enzyme (IDE). 
 
 2 
History and Discovery of the Amyloid Precursor Protein 
 The Amyloid precursor protein and its role in health and disease is 
perhaps best understood in the context of its discovery. During the early 19th 
century the German physician Alois Alzheimer reported the case of a female 
patient with unusually advanced dementia for her age. The patients’ health 
quickly deteriorated and she soon passed away.  Following her death, Alois 
performed an autopsy of the patient’s brain and was surprised to observe what 
would become known as the hallmarks of “Alzheimer’s Disease” (AD). These 
observations included the formation of aggregated “plaques” and  intracellular 
“tangles” in brain tissue as well as changes in the lipid composition of the brain 
(Alzheimer, Stelzmann, Schnitzlein, & Murtagh, 1995). 
 It was not until several decades later that the physical composition of 
these plaques was elucidated by the chemists Glenner and Wong, who revealed 
that these seemingly neurotoxic plaques were actually formed of a self-
aggregating peptide approximately 40 amino acids in length (Glenner & Wong, 
1984). Around this same time it was recognized that the plaques observed in AD 
brains were chemically identical to the plaques found in the brains of aged 
patients with Downs Syndrome (Masters et al., 1985).  
 It was hypothesized that the plaque forming peptide, now termed Amyloid 
Beta (Aβ), may actually be cleaved from a larger protein. The pursuit of this 
hypothesis lead to the landmark discovery of the Amyloid precursor protein 
(APP) in 1987 (Kang et al., 1987). The gene encoding APP in humans was 
confirmed to be located on chromosome 21, thus it is believed that humans 
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afflicted with Downs Syndrome have an extra copy of the gene which results in 
increased APP and consequently more Aβ production (Blanquet et al., 1987; 
Robakis et al., 1987). The discovery of APP and subsequent research revealed 
that it is a transmembrane protein resembling a cell surface receptor and is 
ubiquitous throughout the body, but especially abundant in nervous tissue 
(Selkoe et al., 1988).  
APP in AD: The Amyloid Hypothesis 
 The theory that Alzheimers Disease is caused by the buildup of toxic Aβ in 
the brain known as the Amyloid Hypothesis. After APP was discovered, it was 
generally recognized that for the Aβ peptide to become liberated from the larger 
Amyloid precursor protein, proteolytic enzymes would likely be required. The 
locations of the amino acids within APP that must be hydrolyzed to generate Aβ 
peptide could be logically deduced from the known sequences of APP and Aβ. 
Thus, during the 1990’s several independent research groups sought to identify 
the proteolytic enzymes, termed “secretases” which could cut the APP protein at 
these defined sites. It was hoped that identification of these enzymes could lead 
to pharmacological targets. In 1995 the γ-secretase enzyme was identified, and it 
was revealed that mutations in this enzyme lead to early onset AD (Levy-Lahad 
et al., 1995; Sherrington et al., 1995). This finding, along with the finding that 
certain familial mutations in APP drive another form of early onset AD, greatly 
bolstered the evidence for the Amyloid Hypothesis (Citron et al., 1992). It is now 
accepted that Aβ and its aggregated oligomeric forms are generally neurotoxic. 
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At this present time, the Amyloid Hypothesis remains the dominant theory of AD 
(Selkoe & Hardy, 2016). 
The Physiologic Role of APP 
Structure, Expression and Processing of APP 
 APP is a single pass transmembrane protein with a small intracellular c-
terminal region, and a large extracellular n-terminal region (Kang et al., 1987; U. 
C. Muller & Zheng, 2012). The protein is trafficked to the cell membrane via the 
conventional secretory pathway, and contains a YENPTY motif on its c-terminus 
for clathrin-mediated endocytosis (Jacobsen & Iverfeldt, 2009; Muresan & 
Ladescu Muresan, 2015). Numerous isoforms of the APP gene have been 
reported, but three isoforms in particular seem to be most abundant (Golde, 
Estus, Usiak, Younkin, & Younkin, 1990; Pan, Monteggia, & Giordano, 1993; 
Selkoe et al., 1988). Neurons produce the relatively lower molecular weight 695 
amino acid APP, while most other cell types including glial cells produce the 750 
to 770 amino acid isoforms. Alternative splicing of APP varies with tissue and cell 
type (Nalivaeva & Turner, 2013). Unlike the APP695, the heavier molecular 
weight isoforms of APP contain a Kunitz protease inhibitor domain and heparin 
binding domain which may be important for their function. 
 Mature APP protein can be enzymatically processed by a variety of 
secretases, resulting in the formation of different APP fragments ranging from 
small peptides to large soluble 100 kilodalton proteins. In general, this processing 
is described as “amyloidogenic” or “non-amyloidogenic”, meaning producing or 
not-producing Aβ respectively. Amyloidogenic processing of APP involves the 
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cleavage of APP by the BACE1 enzyme (β-secretase) on the extracellular 
domain, followed by cleavage of APP within the cell membrane by the γ-
secretase protein complex to ultimately yield the Aβ peptide along with a 
secreted APP fragment sAPPβ (Selkoe & Hardy, 2016; Sinha et al., 1999; 
Vassar et al., 1999; Yan et al., 1999). In non-amyloidogenic processing, the APP 
protein is cleaved within the Aβ sequence by one of the many α-secretase 
enzymes resulting in the release of the large sAPPα fragment extracellularly, 
where it is thought to act as a ligand for a variety of receptors (Habib, Sawmiller, 
& Tan, 2017).  
 In addition to processing mechanisms involving the ectodomain of APP, 
the intracellular domain of APP can also be cleaved to yield a short peptide 
fragment known as AICD (APP Intracellular Domain). This AICD region of APP 
contains the YENPTY signal sequence and interacts with a variety of other 
proteins. AICD is thought to be involved in the regulation of gene expression 
(Kimberly, Zheng, Guenette, & Selkoe, 2001).  
The APP Protein Family 
 The APP protein is part of a family of three known proteins including APP, 
APLP1 and APLP2 (U. C. Muller & Zheng, 2012).  Like APP, APLP1 and APLP2 
are both single pass transmembrane proteins. APLP1 and APLP2 are processed 
similarly to APP, but cannot produce Aβ due to the lack of the amyloidogenic Aβ 
sequence within them (Eggert et al., 2004; Li & Sudhof, 2004). APLPs are 
capable of being processed through both α and β secretase processing 
mechanisms. Like APP, the extracellular domain of the APLPs is released into 
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extracellular space when the proteins are cleaved by α-secretase. This protein 
fragment is termed either sAPLP1α or sAPLP2α (Walsh et al., 2007). While APP 
and APLP2 are ubiquitously expressed, APLP1 expression is limited to the brain 
(Lorent et al., 1995; Wasco et al., 1993).  
Functions of APP and APLPs in the Brain and Peripheral Organs 
 The APP family of proteins is widely conserved among species and 
present in numerous multicellular organisms, suggesting the gene is biologically 
important or advantageous in survival and proliferation (Tharp & Sarkar, 2013). 
While the role of APP in the generation of Aβ is now well characterized, the 
physiologic functions of APP are less certain. Studies in transgenic animals have 
revealed that the APP family of proteins is required for survival, implying these 
proteins perform an essential biological function (Heber et al., 2000; Needham et 
al., 2008). Specifically, studies in transgenic mice reveal that mice must express 
either the APP or APLP2 gene in order to survive and develop normally past the 
neonatal stage. Experimental evidence suggests this lethality may be due in part 
to robust deficits in the development of the neuromuscular junction (Klevanski et 
al., 2014; P. Wang et al., 2005). Curiously, this fatal double knockout mouse for 
APP and APLP2 is hypoglycemic before death (Needham et al., 2008). Genetic 
ablation of just APP alone confers a more benign phenotype, with significant 
reductions in mouse brain volume, animal size, body weight, serum glucose and 
changes in whole body metabolism (U. Muller et al., 1994; Needham et al., 2008; 
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Puig et al., 2017; Zheng et al., 1995). As in mice, in the nematode C. elegans, 
ablation of the APP homologue APL-1 is lethal (Ewald & Li, 2012). 
 Functional characterization of the APP family of proteins highlights their 
importance, particularly in the central nervous system. The APP family of 
proteins have been characterized as synaptic adhesion molecules and 
upregulated during synaptogenesis (Schilling et al., 2017). Furthermore, the full 
length APP protein itself is believed to be involved in certain signaling processes 
and may function as a cell surface receptor for extracellular ligands (Hass & 
Yankner, 2005; Kang et al., 1987; B. Wang et al., 2017). APP and sAPPα play a 
role in neurite outgrowth and neuronal migration (Gakhar-Koppole et al., 2008; 
Hasebe et al., 2013; Ramaker, Swanson, & Copenhaver, 2016). sAPPα has also 
been shown function as a neurotrophic factor and may play neuroprotective role 
in the central nervous system (Fol et al., 2016; Hick et al., 2015; Weyer et al., 
2011). Additionally, characterization of aged APP-/- mice has revealed that these 
animals have fewer dendritic spines in addition to learning deficits (K. J. Lee et 
al., 2010; Tyan et al., 2012). Taken together, these studies suggest APP and its 
metabolites influence a variety of cellular processes within the brain and are of 
particular importance in synapse development and function. 
 Outside of nervous cells, APP has been implicated in a diverse set of 
biological processes. In immune cells, APP has been demonstrated to be 
upregulated under pro-inflammatory conditions and may serve roles in cell 
migration and adhesion as well as regulating general immune cell phenotype 
(Banati et al., 1993; Manocha et al., 2016; Puig et al., 2017; Sondag & Combs, 
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2004, 2010). In the skin, APP has a role in regulating cell proliferation and 
maturation (Herzog, Kirfel, Siemes, & Schmitz, 2004; Hoffmann, Twiesselmann, 
Kummer, Romagnoli, & Herzog, 2000). In skeletal muscle tissue, sAPPα has 
been shown to potentiate glucose uptake and APP localizes to the 
neuromuscular junction with acetylcholine receptors (Hamilton et al., 2014; P. 
Wang et al., 2005). APP is also present is adipose tissue, where it seems to be 
upregulated under certain pro-inflammatory conditions and through certain 
cytokines (Puig, Floden, Adhikari, Golovko, & Combs, 2012; Sommer et al., 
2009). APP can be detected in intestinal tissue associated enteric nervous 
system. Its presence plays a role in nutrient uptake and overall intestinal 
phenotype (Puig, Lutz, et al., 2015; Puig, Manocha, & Combs, 2015; Puig, 
Swigost, Zhou, Sens, & Combs, 2012). These studies are but a fraction of the 
wide array of research documenting the varied and numerous roles of APP in 
peripheral organs. With increasing research it is becoming clear that the role of 
APP in each tissue changes depending on the physiological function of the organ 
and the types of proteins which can both interact with and process APP locally.  
General Overview of AD 
 Alzheimer’s disease has become the most prevalent neurodegenerative 
diseases and a leading cause of death of the elderly. Approximately 5.5 million 
people in the United States are currently afflicted with AD, and the incidence of 
the disease is expected to rise to approximately 13.8 million people by 2050 
(Taylor, Greenlund, McGuire, Lu, & Croft, 2017). AD is progressive and 
neurodegenerative, and is characteristic in its progression by affecting particular 
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regions of the brain more prominently than others. The limbic system and 
temporal lobes, including the hippocampal formation of the brain are dramatically 
affected and show pathological changes early in the disease (Braak & Braak, 
1997a, 1997b). Pathological hallmarks of AD include Aβ plaque deposits in the 
brain and blood vessels, as mentioned above, and the hyperphosphorylated 
protein Tau which forms intracellular tangles. The regions of the brain affected 
are critically involved in both the formation and storage of memories, thus their 
degeneration results in the notorious phenotype of memory which occurs in AD 
(Teyler & Rudy, 2007). In addition, notable language impairment and spatial 
memory deficits are observed in AD (Morello, Lima, & Brandao, 2017). At this 
time there are no available cures for the disease. Therapies which combat the 
symptoms of AD are available, but limited in their effectiveness (C. Zhang, 2017). 
Ultimately, affliction with AD results in the death of the patient. In the United 
States 3.6% of all premature death is due to AD (Taylor et al., 2017).  
Metabolic Dysfunction and Alzheimer’s Disease 
Brain Glucose Hypometabolism in Alzheimer’s Disease 
 Glucose is essential for normal brain function and brain development 
(Burns, Rutherford, Boardman, & Cowan, 2008; Cornblath & Reisner, 1965). 
While the brain can utilize ketones as a source of fuel during prolonged fasting 
and starvation, glucose serves as the primary energy source for the brain.  
Severe hypoglycemia results in coma and eventually, death. To preserve 
function and survival, the brain tightly regulates blood glucose levels and food 
intake (Xu, O'Malley, & Elmquist, 2017). The brains ability to regulate blood sugar 
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was first demonstrated by the French physiologist Claude Bernard in 1854. 
Bernard found that by lesioning the floor of the brain’s fourth ventricle in rabbits 
blood sugar levels would subsequently increase (Tups, Benzler, Sergi, Ladyman, 
& Williams, 2017).  
 In the 1980s, the German physician-scientist Siegfried Hoyer was the first 
to hypothesize that metabolic dysfunction may play a role in the pathogenesis of 
Alzheimer’s disease and age related cognitive decline. In his time, Hoyer’s 
theories were controversial as they challenged the more traditional “plaques and 
tangles” view of AD. Specifically, Hoyer observed that glucose metabolism was 
significantly impaired in the brain of patients with advanced AD, compared to 
aged matched controls (Hoyer, 1982, 1986). In one patient cohort, he observed 
more than a 40% reduction in the metabolic rate of glucose of AD patients 
(Hoyer, Oesterreich, & Wagner, 1988). Hoyer’s seminal observations have been 
further validated over the years by several researchers (Meier-Ruge, Bertoni-
Freddari, & Iwangoff, 1994; Sugimoto et al., 2017). This pattern of impaired and 
regional glucose hypometabolism is not restricted to AD, but is also observed in 
aged patients with Downs syndrome (Lao et al., 2018). Curiously, this 
phenomenon in some cases seems to precede, and cannot solely be explained 
by, changes in gray matter volume in the brain (Wirth et al., 2017). Glucose 
hypometabolism is also observed in the brains of various animal models of AD 
(Dodart, Mathis, Bales, Paul, & Ungerer, 1999; Macdonald et al., 2014; Sadowski 
et al., 2004). In the McGill-R-Thy1-APP rat model of AD, which overexpresses a 
human mutant APP to produce Aβ aggregates in the brain, glucose 
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hypometabolism is observed in aged animal brains along a similar time course 
with development of Aβ plaque deposits (Parent et al., 2017). This observation, 
which is dependent on brain cells taking up the radiofluorinated glucose molecule 
[18F]FDG, has been shown to be a signal of impaired energy consumption in both 
neurons and astrocytes (Zimmer et al., 2017). The time course of brain 
hypometabolism across AD animal models and its detectability in Aβ driven 
models of AD suggest Aβ may be the primary molecular mediator of this 
phenomenon. However, this does not preclude the possibility that 
hypometabolism is critically involved in the pathophysiology and development  
of AD. 
Insulin and Insulin Receptor in the Brain 
 For several decades, it was believed that insulin does not play an 
important role in brain physiology. This assumption was based on the 
experimental observation that brain glucose uptake is not robustly stimulated by, 
or dependent on, insulin in vivo (Best, Taborsky, Halter, & Porte, 1981; Goodner, 
Hom, & Berrie, 1980; Hertz, Paulson, Barry, Christiansen, & Svendsen, 1981). 
Furthermore, the cells of the brain including neurons were found to utilize 
different glucose transporters than the insulin sensitive muscle and adipose cells. 
Neurons primarily utilize the high affinity transporter Glut3, while skeletal muscle 
and adipose tissue express insulin responsive Glut4 (Stringer, Zahradka, & 
Taylor, 2015). The brain was thus deemed to be an insulin-insensitive organ. 
However, more recently, numerous research findings have done much to shift 
this paradigm and it is now generally accepted that both insulin and the insulin 
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receptor play a significant role in brain function and brain regulation of peripheral 
metabolism (Kleinridders, Ferris, Cai, & Kahn, 2014).  
 While the vast majority of insulin in the human body is synthesized in the β 
cells in the islets of Langerhans of the pancreas, both the insulin peptide and 
insulin mRNA are detectable in the brain, suggesting the brain may produce 
small amounts of insulin locally (Devaskar et al., 1994; Devaskar, Singh, 
Carnaghi, Rajakumar, & Giddings, 1993). Insulin has also been detected in 
primary neuron cultures (D. W. Clarke, Mudd, Boyd, Fields, & Raizada, 1986). In 
addition, insulin is actively transported across the blood-brain barrier (Baura et 
al., 1993). Increases in peripheral insulin have been shown to activate insulin 
signaling in specific regions of the brain (Kleinridders et al., 2013). The insulin 
receptor (IR) is distributed throughout the brain including the olfactory bulb and 
hypothalamus and is particularly abundant in the hippocampus, cortex and 
thalamus (Kleinridders et al., 2014). Much of what is known about the role of the 
insulin receptor in the brain comes from the brain-specific IR knockout mouse 
generated by the lab of Dr. Ronald Kahn (Bruning et al., 2000). These animals 
show changes in feeding behavior, become obese and insulin resistant and also 
develop hypothalamic dysfunction. Thus, brain IR is thought to play an essential 
role in regulating metabolism in the periphery. Additionally, insulin is thought to 
participate in the normal function of the brain. Infusion of insulin into the rat brain 
improves performance in spatial memory tasks (Biessels et al., 1998; Park, 
Seeley, Craft, & Woods, 2000). The hippocampus is essential for learning and 
memory and insulin is now believed to play an important role in hippocampal 
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function. Insulin has been shown to modulate the activity of hippocampal neurons 
and likely plays an important role in synaptic plasticity and long term potentiation 
(van der Heide, Kamal, Artola, Gispen, & Ramakers, 2005).  This finding has 
been further validated by the fact that insulin has been shown to have 
comparable roles in activating signaling cascades and affecting neuron function 
in other neuronal types (Klockener et al., 2011). In stark contrast to the previous 
dogma of insulin’s role in the brain, recent evidence also suggests insulin plays a 
surprising role in brain energy utilization. In astrocytes, which are the most 
abundant cell in the brain, insulin has been shown to enhance glucose uptake 
and regulate metabolism. Insulin, in cooperation with the related insulin-like 
growth factor 1 (IGF-1) enhances glucose uptake by regulating the activity and 
subcellular location of the Glut1 transporter (Fernandez et al., 2017; Hernandez-
Garzon et al., 2016). Furthermore, insulin mediated astrocyte glucose uptake is 
critical for brain regulation of peripheral metabolic processes and also regulates 
glucose flux across the blood-brain barrier (Garcia-Caceres et al., 2016).  
Insulin and Insulin Resistance in Alzheimer’s Disease 
 Given the important roles of insulin in the brain it is not surprising that 
insulin resistance is associated with cognitive dysfunction and 
neurodegeneration. Human patients with type 1 or type 2 diabetes have 
accelerated cognitive decline as they age, in addition to behavioral changes 
(Biessels, Deary, & Ryan, 2008). Furthermore, epidemiological evidence has 
implicated type 2 diabetes (T2DB), or insulin resistance, as a risk factor for AD, 
and T2DB has been shown to more than double the risk of developing late onset 
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AD (Mittal & Katare, 2016; Vagelatos & Eslick, 2013). Metabolic dysfunction in 
general, including obesity, also accelerates the progression of cognitive decline 
and dementia (Beydoun, Beydoun, & Wang, 2008). Some researchers are now 
considering Alzheimer’s disease as a third form of diabetes, or type 3 diabetes 
(de la Monte, 2014). This hypothesis states that insulin resistance in the brain is 
a causative factor in AD. The experimental basis of this hypothesis is largely 
grounded in the work published by Talbot et. al in 2012 (Talbot et al., 2012). 
Talbot performed human brain tissue slice cultures from both AD patients and 
age matched controls. These slices were then stimulated with near physiologic 
levels (1-10 nM) of either insulin or IGF-1, and the induction of the insulin 
signaling cascade was measured by assessing multiple markers including 
phosphorylation of the insulin receptor and other downstream markers such as 
pAKT and pIRS. Talbot observed significant insulin signaling resistance and IGF-
1 signalling resistance in the AD brain, including in the hippocampus. This 
provided the first experimental evidence demonstrating significant insulin 
resistance in the human AD brain. 
 The relationship between insulin and AD extends to animals models. In 
modeling type 1 diabetes, a disease of insufficient insulin production, researchers 
often utilize the toxin streptozotocin (STZ). STZ selectively kills the insulin-
producing β cells of the pancreas, resulting in insulin insufficiency and 
consequently hyperglycemia. It has been found that monkeys treated with STZ 
develop AD-like pathology in the brain. This includes increased levels of Aβ in 
the hippocampus, changes in Tau phosphorylation and perturbations of several 
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insulin signaling markers within the brain (Morales-Corraliza et al., 2016). 
Injections of Aβ oligomers into the monkey brain also cause insulin resistance 
directly in the CNS, an effect which is rescued with insulin sensitizing GLP-1 
receptor agonists (Bomfim et al., 2012). Hyperglycemia, glucose intolerance and 
insulin resistance have been noted across several mouse models of AD. These 
metabolic perturbations occur as a function of age and are exacerbated by high 
fat diet or STZ-induced insulin insufficiency, suggesting that maintaining 
peripheral metabolic homeostasis is an important factor in the progression of the 
AD phenotype (de la Monte, Tong, Schiano, & Didsbury, 2017; Macklin et al., 
2017; Vandal et al., 2015; Vandal et al., 2014). Hyperglycemic clamp and 
microdialysis experiments in rodents demonstrate that hyperglycemia alone is 
sufficient to drive increased production of Aβ in the CNS in vivo (Macauley et al., 
2015). Interestingly, Aβ alone may not be the sole mediator of insulin 
dysregulation in the brain. In addition to Aβ deposits in the brain, intracellular Tau 
“tangles” are a known pathological feature of the AD brain. Tau has recently 
been identified to being a potent regulator of insulin signaling in the brain, and 
deletion or loss of function of Tau drives brain insulin resistance (Marciniak et al., 
2017). 
 In addition to the view that peripheral metabolic defects may drive the 
pathogenesis of AD, experimental evidence also suggests that increasing Aβ 
concentrations in the brain is sufficient to induce diabetes and aberrant whole-
body metabolism. Intracerebroventricular injections of Aβ oligomers into the 
brains of mice results in peripheral glucose intolerance, possibly due to damage 
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induced to the hypothalamus. In TNFα receptor knockout mice increasing brain 
Aβ does not result in glucose intolerance, suggesting that inflammation plays a 
necessary role in this phenomenon (J. R. Clarke et al., 2015). Brain-specific 
knock-in of BACE1 (β-secretase) causes diminished brain glucose uptake and 
systemic diabetes as a function of age, suggesting that increased brain amyloid 
burden is the direct mediator of peripheral metabolic dysfunction observed in 
Alzheimer’s  (Plucinska et al., 2016). In total, these studies demonstrate that 
peripheral metabolism and insulin production play a direct role in regulating the 
progression of AD in the brain, and conversely, that the health of the brain plays 
a direct role in regulating peripheral metabolism and insulin sensitivity.  
Aβ as a Promoter of Insulin Resistance  
 In vitro experiments have provided additional mechanistic insight into the 
role of the Aβ peptide in disrupting insulin signaling. The Aβ peptide monomer 
has been shown to directly bind the insulin receptor. Binding of Aβ to the IR is 
competitive with insulin and does not stimulate IR. Increasing concentrations of 
Aβ inhibit IR phosphorylation and downstream signaling in the presence of 
insulin, thus Aβ acts something like a competitive antagonist. This antagonistic 
effect of Aβ for the IR is observed for both the 40 and 42 amino acid lengths of 
the Aβ peptide and interestingly, is not observed if the sequence of amino acids 
in Aβ is modified (Xie et al., 2002). It is reasonable to question if Aβ-IR 
interaction occurs in vivo. The estimated Ki of this competitive interaction is in the 
micromolar range (8 µM). This far exceeds the normal physiologic concentrations 
of Aβ in human cerebral-spinal fluid which are in the nanomolar range or less 
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(Schirinzi et al., 2017). Micromolar concentrations of Aβ have also been shown to 
antagonize the effect of insulin when applied to rat hippocampal and cortical 
synaptosomes (Heras-Sandoval, Ferrera, & Arias, 2012). Insulin signaling in 
cultured cells has been shown to be disrupted by intracellular Aβ, which may 
have more relevance in vivo (H. K. Lee, Kumar, Fu, Rosen, & Querfurth, 2009). 
 Curiously, Aβ and sAPPα seem to have antagonistic effects on insulin 
receptor signaling. Stimulation of muscle or neuronal cultures with sAPPα 
induces insulin signaling and has neuroprotective effects (Hamilton et al., 2014; 
Jimenez et al., 2011). Viral mediated sAPPα overexpression has been shown to 
have pro-cognitive effects in an AD mouse model (Fol et al., 2016). Furthermore, 
stimulation of cells with insulin or sAPPα shifts APP processing from 
amyloidogenic processing to non-amyloidogenic processing (Son et al., 2012; X. 
Wang et al., 2014). sAPPα in particular has been shown to decreased BACE1 
activity to reduce Aβ production (Obregon et al., 2012). However, insulin has 
been shown to potentiate Aβ secretion in some cell types, though the effect of 
this on AD progression is uncertain (Najem, Bamji-Mirza, Yang, & Zhang, 2016; 
Tharp et al., 2016). Aβ oligomers have also been shown to inhibit insulin receptor 
signaling in cultured cells. Treatment of primary hippocampal neuron cultures 
with Aβ oligomers has been shown to downregulate IR expression (Liu et al., 
2014). It is possible to some extent that Aβ induced insulin resistance observed 
in vivo is a secondary consequence of inflammation. Aβ oligomers are potent 
pro-inflammatory agents, and inflammation has long been known to have a role 
in inducing insulin resistance in tissues (Hotamisligil, 2006). Indeed, it has been 
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shown that the some of the deleterious effects of Aβ oligomers on cognition are 
dependent on promoting inflammation to impair insulin signaling (Lourenco et al., 
2013). 
Insulin Degrading Enzyme in Alzheimer’s Disease 
 While mechanisms involving Aβ production have been the subject of 
extensive research efforts, much less is known about Aβ clearance mechanisms 
and their role in AD. During the 1990’s two enzymes were independently 
identified as having the ability to catabolize the Aβ peptide; neprilysin (NEP) and 
insulin degrading enzyme (IDE) (Howell, Nalbantoglu, & Crine, 1995; Kurochkin 
& Goto, 1994). IDE is of particular interest because of its role in clearing insulin 
from tissues, thus making it critically important in regulating insulin signaling. In 
humans, IDE is located on chromosome 10 (Espinosa et al., 1991). Damage to 
chromosome 10 in the region of IDE has been associated as conferring an 
increased risk of developing AD (Bertram et al., 2000). Furthermore, tissue 
samples from human families that are known to develop AD and also have 
mutations in chromosome 10 have been shown to have decreased IDE activity 
(Kim et al., 2007). These studies indicate IDE plays an important role in 
protecting the brain against the development of AD. IDE polymorphisms have 
also been found to be associated with the development of type 2 diabetes 
(Karamohamed et al., 2003). 
 IDE is expressed throughout the body and plays an important role in 
clearing insulin from traditionally insulin-sensitive tissues (Bondy et al., 1994). 
When insulin stimulates its canonical receptor, the insulin-receptor complex can 
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be endocytosed and the bound insulin degraded by IDE, or returned to the 
plasma membrane and released back into circulation (Levy & Olefsky, 1987). 
IDE has been shown to play a role in regulating cellular sensitivity to insulin 
signaling. Degraded insulin peptide fragments still have some ability to bind and 
activate the insulin receptor (Duckworth, 1988). The majority of IDE is located in 
the cytosol, but the enzyme is also detected in endosomes, lysosomes and 
mitochondria and is secreted in exosomes (Duckworth, Bennett, & Hamel, 1998). 
Interestingly, IDE substrates are not determined by the presence of a particular 
amino acid sequence, but by relative size and charge. In addition to insulin and 
Aβ, IDE has been shown to degrade a wide range of substrates including amylin, 
glucagon and the AICD fragment of APP (Kurochkin, Guarnera, & Berezovsky, 
2018). 
 IDE is detectable in all of the major cell types of the brain including 
neurons (Vekrellis et al., 2000). Microglia have also been reported to secrete IDE 
which may play an important role in Aβ plaque clearance from the brain (Qiu et 
al., 1998). Insulin competitively inhibits the degradation of Aβ by IDE, thus it has 
been speculated that the hyperinsulinemia observed in type 2 diabetes may slow 
clearance of Aβ in brain tissue (Kurochkin & Goto, 1994). IDE is one of the 
strongest molecular links connecting AD and diabetes to date. 
Intranasal Insulin as Therapeutic Agent in Alzheimer’s Disease 
 Given the important role of insulin in normal brain function and the 
demonstrated insulin resistance observed in AD derived brain tissues, it stands 
to reason that enhancing insulin signaling in the brain may serve as a therapeutic 
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strategy to combat AD. However, increasing insulin concentrations in the brain 
without altering systemic insulin levels and signaling represents a 
pharmacokinetic challenge. Interestingly, intranasal administering of the insulin 
peptide represents a possible solution. This possibility has now been tested in 
humans and animals with remarkable results. In humans, it has been shown that 
intranasal administration of insulin peptide results in significantly increased 
concentrations of insulin peptide within the cerebral spinal fluid within 10 minutes 
and peaks 30 minutes (Born et al., 2002). Importantly, intranasal insulin 
administration does not robustly change plasma insulin concentrations. This 
method of dosing insulin directly to the brain has also been demonstrated to work 
in rodents (Salameh et al., 2015). Intranasal insulin administration has been 
tested in mouse models of AD and has shown positive effects on memory and 
cognition. Long term administration of intranasal insulin has shown shown to 
promote neuron survival and stimulate insulin signaling (Apostolatos et al., 2012). 
Additionally, in AD mice, long term intranasal insulin promotes neurogenesis and 
rescues memory defects (Mao et al., 2016; Y. Zhang et al., 2016).  
 Clinical trials in humans utilizing intranasal insulin to attenuate cognitive 
and memory deficits are currently ongoing. Evidence to this point has been 
positive, suggesting that both acute and long-term administration improves 
cognitive performance (Claxton et al., 2015; Craft et al., 2012; Craft et al., 2017). 
This includes improved performance in verbal memory scores and selective 
attention. At this time however, studies in ApoE4 allele patients are mixed. 
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ApoE4 is a potent risk factor for AD and some evidence suggests intranasal 
insulin is not effective in these patients (Rosenbloom et al., 2014).  
 The apparently promising results of these early clinical trials, prevalence 
of AD in human populations and mounting evidence that insulin signaling and 
resistance play a prominent role in the pathology of AD warrant the need for 
additional studies into the biology of insulin in AD mediated neurodegeneration. 
Dissertation Research Objective 
 This dissertation is intended to continue our laboratory’s efforts to 
characterize the physiologic functions of APP and to also gain a greater 
understanding of the relationship between insulin and Alzheimer’s disease. Our 
lab has focused on understanding the biology of APP in a number of peripheral 
organs including intestine, immune and adipose tissue in order to gain a greater 
understanding of APP’s biology and its potential role in disease. Our attention is 
primarily focused on APP function and processing and to look for downstream 
changes which may be induced by APP loss or overexpression. The objective of 
this dissertation is to characterize APP’s role in insulin homeostasis. We focus on 
pancreatic dysfunction as it is a well-known factor in insulin resistant diabetes. 
We also focus on the insulin degrading enzyme because of its established link as 
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an enzyme linking diabetes and AD. This dissertation is broken into two studies 
aimed at addressing the following questions: 
 1. What role does APP play in the function and pathophysiology of the 
endocrine pancreas?  
 2. What is the relationship between APP and IDE expression and activity? 
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CHAPTER II 
METHODS 
Animals 
 The APP knockout mice (APP-/-) strain B6.129S7-Apptm1Dbo/J,  the 
APP/PS1 transgenic mouse line, strain 005864 B6.Cg-Tg 
(APPswe,PSEN1dE9)85Dbo/ Mmjax and wild type mouse line, C57BL/6, were 
purchased from the Jackson Laboratory (Bar Harbor, Maine). The APP-/- mice 
have the APP gene knocked out in the entire organism by the insertion of a 
neomycin resistance cassette into the promoter region and Exon 1 of the APP 
gene. The APP/PS1 mice express the Swedish mutation in APP and deltaE9 
mutation in the PS1 gene under the control of the mouse prion promoter. 
APP/PS1 mice have been shown to develop AD-like Aβ plaques within the brain 
around 6 months of age. Females from all three strains of mice were collected at 
2 and 12 months of age for analysis. 
Animal Use 
 All animal use was approved by the University of North Dakota 
Institutional Animal Care and Use Committee (UND IACUC) protocols 1505-4 
and 0712-1C. Mice were provided food and water ad libitum and housed in a 12 
h light/dark cycle. The investigation conforms to the National Research Council of  
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the National Academies Guide for the Care and Use of Laboratory Animals (8th 
edition). 
Human Tissue 
 Acetone fixed 10µm healthy and diseased human pancreatic tissue 
sections were obtained from Bio-Chain (Newark, CA, USA). Isolated pancreatic 
islets were obtained from Prodo Labs (Aliso Viejo, CA, USA). Tissue use was 
approved by the UND Institutional Review Board (protocol IRB-200412-198). 
Western Blots 
 Whole pancreas, isolated murine islets and isolated human islets were 
lysed in RIPA Buffer containing protease inhibitor (Sigma P8340, St. Louis, MO, 
USA) on ice. Protein concentrations were determined using the Bradford method 
(Bradford, 1976). In study II, Hippocampus, gastrocnemius muscle, liver and 
primary cell cultures were lysed in RIPA Buffer containing protease inhibitor 
(Sigma P8340, St. Louis, MO, USA) on ice. Protein concentrations were 
determined using the Bradford method 5-10 µg of protein was resolved by 10% 
SDS-PAGE and transferred to PVDF membranes. Membranes were blocked for 
1 hour in 5% BSA-TBST solution and then incubated overnight in 5% BSA-TBST 
solution containing the primary antibody. The next day primary antibodies were 
washed off the membrane with TBST and HRP-conjugated secondary antibodies 
were applied to membranes in 5% BSA-TBST for 2 hours. Luminol 
chemiluminescence was utilized for visualization of proteins. 
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Immunohistochemistry/Immunofluorescence 
 Pancreatic tissue was fixed in 4% paraformaldehyde (PFA) and cut into 
10µm serial sections by cryostat. Mouse brains were fixed in 4% PFA, embedded 
in gelatin, and serial sectioned to a thickness of 40µm using a sliding microtome. 
The tissue was incubated overnight in primary antibody diluted in a PBS based 
solution (1% Triton X-100, 3% BSA, 2% horse serum). Vector VIP (Vector Labs, 
Burlingame, CA, USA) was used as the chromogen for visible light microscopy. 
For immunofluorescent co-localization, Alexa Fluor 594 and Alexa Fluor 
488 conjugated secondary antibodies (Life Technologies, Carlsbad, CA, USA) 
were used with a DAPI counterstain. Nonspecific binding of secondary antibodies 
was assessed by applying only the secondary antibody in blocking PBS solution. 
BACE2 epitope blocking peptide studies were conducted by incubating tissue 
with 1 µg/mL anti-BACE2 antibody with or without 2 µg/mL BACE2 blocking 
peptide (Abcam ab8392, Cambridge, UK). BACE2 staining was quantified by 
using Photoshop CS6 software. Images of islets were converted to greyscale and 
traced around the periphery to assess total islet BACE2 staining intensity. The 
total islet staining intensity was divided by the total area assessed to normalize 
for islet size. A total of twelve non-serial sections from 12 month old animals 
(n=8) from each strain were stained and assessed in this manner. A minimum of 
twenty islets from each strain of mice was analyzed for its BACE2 staining   
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intensity. Values obtained from this analysis were normalized to the mean 
staining intensity value of the wild type strain. 
Thioflavin S Staining 
 Thioflavin S staining was optimized in APP/PS1 mouse brain tissue and 
then performed in pancreatic tissue by first quenching endogenous fluorescence 
by incubating slides in 0.2% Sudan Black dissolved in 50% ethanol for 5 minutes. 
Slides were then washed in PBS and then incubated in 0.02% thioflavin S 
dissolved in dH2O for 30 minutes. Slides were washed again in PBS then 
dehydrated and coverslipped in Permount. 
Antibodies 
 Antibodies against full length APP (ab32136), BACE2 (ab8025), glucagon 
(ab10988), IDE (ab32216) and the insulin receptor (ab69508) were purchased 
from Abcam (Cambridge, UK). Antibodies against insulin (L6B10), p-GSK3β 
(D3A4), GSK3β (D5C5Z), p-AKT (193H12) and AKT (C67E7) were purchased 
from Cell Signaling Technology, Inc. (Danvers, MA, USA). The monoclonal 
4G8 antibody targeting the Aβ peptide used in these studies was purchased from 
Covance (Princeton, NJ, USA) and is now available from Biolegend (San Diego, 
CA, USA). Antibodies against the N-terminus of APP (MAB348), GLUT2 (07-
1402), and GLUT4 (07-1404) were purchased from Millipore (Darmstadt, 
Germany). Antibodies against GLUT1 (sc-7903), GLUT3 (sc-7682), and ZNT8 
(sc-98243) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, 
USA).The antibody for amylin (250470) was purchased from Abbiotec (San 
Diego, CA, USA). The antibody against human APP (803001) was purchased 
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from Biolegend (San Diego, CA, USA). The antibody against Aβ oligomers 
(11610) was purchased from Cayman Chemical (Ann Arbor, MI, USA). The 
antibody against neprilysin (MAB1126) was purchased from R&D Systems 
(Minneapolis, MN, USA). 
Enzyme Linked Immunosorbent Assays (ELISA) 
 Human Aβ ELISA kits (Millipore, Darmstadt, Germany) were utilized for 
quantitation of tissue and islet culture Aβ. Whole pancreas tissue was lysed in 
radioimmunoprecipitation assay buffer (RIPA) to yield detergent soluble Aβ. Aβ in 
islet cultures was assessed by hand picking islets directly from culture and lysing 
20 islets of similar size from each animal in 100µl SDS-free Triton X-100 buffer. 
This lysate was then pulse sonicated and the lysate Aβ immediately measured by 
ELISA. To assess islets for quantitation of total pancreatic insulin and insulin 
secretion from murine islets, a mouse insulin ELISA kit (Millipore ZRMI-13K, 
Darmstadt, Germany) was used. Total pancreatic glucagon content was 
assessed using a glucagon ELISA kit (R&D Systems, Minneapolis, MN, USA). 
Tissue samples were normalized by total sample protein as determined by the 
Bradford method. Human islet insulin secretion was quantified using a human 
insulin ELISA kit (Invitrogen KAQ12511, Carlsbad CA, USA). ELISAs were 
performed as recommended by the manufacturer’s instructions. Hippocampus 
tissue was lysed in radioimmunoprecipitation assay buffer (RIPA) on ice. The 
lysate was sonicated on ice. To assess total hippocampus insulin content a 
mouse insulin ELISA kit (Millipore) was used. Insulin content was normalized to 
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total sample protein as determined by the Bradford method. ELISAs were 
performed as recommended by the manufacturer’s instructions. 
Pancreatic Islet Isolation and Culture 
 Pancreatic islets were isolated from C57BL/6 and transgenic mice using 
modifications of prior methods (Stull, Breite, McCarthy, Tersey, & Mirmira, 2012; 
Szot, Koudria, & Bluestone, 2007). The pancreas was first perfused by 
cannulating the bile duct with a combination of 1 mg/mL collagenase and 
thermolysin (products C9407 and P1512, Sigma Aldrich, St. Louis, MO, USA) in 
a sterile HBSS solution.  The hepatic bile duct was closed using silk sutures prior 
to protease injection to direct fluid into the pancreas. Whole pancreas was then 
removed and placed in 50mL tubes containing HBSS on ice. To initiate digestion, 
the tubes were then placed in a 37 degree water bath and digestion was 
monitored with intermittent mechanical disruption. After approximately 10 to 15 
minutes, islets were then isolated from crude tissue extract by density 
centrifugation along a Histopaque (Sigma Aldrich, St. Louis, MO, USA) gradient 
before further purification using 70 µm filters. Islets from individual animals were 
cultured separately in RPMI 1640 (Sigma Aldrich, St. Louis, MO, USA) containing 
5 mM glucose, 10% FBS, 1% glycine and 1% penicillin/neomycin/streptomycin. 
Human cadaveric pancreatic islets were obtained from Prodo Labs (Aliso Viejo, 
CA, USA) and cultured in RPMI 1640 (Sigma Aldrich, St. Louis, MO, USA) 
containing 5 mM glucose, 10% FBS, 1% glycine and 1% 
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penicillin/neomycin/streptomycin for 24 hours before experiments were 
conducted. 
Min6 Cell Line Culture and Glucose Stimulated  
Insulin Secretion (GSIS) Assay 
 
 The murine MIN6 beta cell line was purchased from Addexbio 
Technologies (San Diego, CA, USA). MIN6 cells were cultured in DMEM/F12 
media (ThermoFisher Scientific, Waltham, MA, USA) supplemented with 15% 
FBS and 0.05 mM 2-mercaptoethanol. MIN6 pseudoislets were produced by 
seeding MIN6 cells in low-attachment cell culture plates (Product #3471) 
(Corning Incorporated, NY, USA). Three days after seeding and pseudoislet 
formation, MIN6 pseudoislets were utilized in a GSIS assay. Pseudoislets were 
first removed from cell culture media by wheel pipette and placed into Krebs 
Ringer buffer (137 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5 
mM CaCl2, 25 mM NaHCO3) containing .05% BSA and 3.7 mM glucose for 60 
minutes. Following incubation, pseudoislets were placed in fresh Ringer buffer 
and then ten pseudoislets of similar size were selected by wheel pipette and 
placed into 1.5 mL tubes containing 300 µL Krebs Ringer Buffer with 3.7 or 16.7 
mM glucose and 0.05% BSA. For sAPPα (Product S9564, St. Louis, MO, USA) 
stimulation experiments, the glucose solution was supplemented with 1 or 10nM 
sAPPα. After 1 hour of stimulation, supernatants were collected and frozen at -80 
degrees. Insulin concentration was determined in supernatants using mouse 
insulin ELISA kit (Millipore ZRMI-13K, Darmstadt, Germany). 
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Human and Mouse Primary Islet Culture Glucose  
Stimulated Insulin Secretion (GSIS) Assay 
 
 Human or murine islets were cultured for 24 hours in RPMI 1640 with 
5 mM glucose and 10% FBS. Islets were hand-picked from culture and incubated 
for 1 hour prior to the GSIS assay in Krebs Ringer buffer (137 mM NaCl, 4.7 mM 
KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5 mM CaCl2, 25 mM NaHCO3) 
containing .05% BSA and 3.7 mM glucose. Following incubation, the islets were 
placed in fresh Ringer buffer.  8-10 islets/experiment were then hand selected 
and placed into sterile 1.5 mL tubes containing 300 µL Krebs Ringer Buffer with 
glucose and BSA. For sAPPα (Product S9564, St. Louis, MO, USA) stimulation 
experiments, the glucose solution was supplemented with 10nM sAPPα. For 
human islet stimulations, a range of glucose concentrations were used (3.7, 10, 
and 16.7 mM) to span from low to high concentrations. Due to limitations in 
animal numbers of the WT, APP-/-, and APP/PS1 genotypes as well as the 
increased time required to hand select islets from the 3 genotypes for multiple 
conditions in the time sensitive GSIS assay, we chose the 5mM glucose 
concentration for the murine islet stimulation since it is physiologically relevant 
and we had observed the strongest and most consistent effect of sAPP 
stimulation of human islets near this concentration. After one hour, supernatants 
were frozen at -80 degrees. Samples were thawed and diluted using sterile 
Ringer’s buffer prior to ELISA. 
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Glucose Tolerance Testing 
 Study I: Two month old WT, APP-/-, and APP/PS1 animals were fasted for 
5 hours before receiving 2g/kg glucose by oral gavage. Prior to gavage and at 
times 15 minutes, 30 minutes, one hour and two hours after gavage blood 
glucose was measured by tail clipping and the TRUEresult glucometer (Home 
Diagnostics, Inc, Fort Lauderdale, FL, USA) 
 In study II, 12 month old male and female WT and APP-/- were fasted for 
5 hours before receiving 2g/kg glucose by IP injection. Prior to injection and at 
times 15 minutes, 30 minutes, one hour and two hours after gavage blood 
glucose was measured by tail clipping and the TRUEresult glucometer. 
RNA Extraction and RT-qPCR 
 Total RNA from hippocampal tissues (10mg) were isolated using Trizol 
Reagent (Thermo Fisher Scientific, Waltham, MA) according to the 
manufacturer’s instruction. Briefly, the tissue samples preserved in Allprotect 
Tissue Reagent (Qiagen Inc., Valencia, CA) were washed once with PBS and 
homogenized in a Bullet Blender Storm 24 tissue homogenizer (Next Advance, 
Inc., Averill Park, NY) using 5mm stainless-steel beads (Qiagen). Extracted RNA 
samples were quantified using a NanoDrop spectrophotometer (Thermo Fisher 
Scientific).  
 For each sample, a cDNA library was generated from 1 µg of total RNA 
using iScript Reverse Transcription Supermix (Bio-Rad Laboratories, Hercules, 
CA) per manufacturers specifications. A primer set for Ide (forward: 5’-
CTGTGCCCCTTGTTTGATGC-3’; reverse: 5’-GTTCCCCGTAGCCTTTTCCA-3’) 
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previously described (Kurauti et al., 2017) and purchased from Millipore Sigma 
(St. Louis, MO).  qPCR was performed in triplicates using iTaq Universal SYBR 
Green Supermix and CFX96 Touch™ Real-Time PCR Detection System with 
CFX Manager Software 3.0 (Bio-Rad) as the operating platform. Ribosomal 
protein S18 (PrimePCR SYBR Green Assay Rsp18, Bio-Rad) was used as a 
reference gene and Rsp18 Cq values were used to normalize respective Ide Cq 
values (ΔCq). Relative Ide mRNA expression was determined as 2-ΔCq and 
shown as mean ± SEM for each mouse strain. 
siRNA Knockdown of APP 
 siRNA mediated knockdown of the mouse APP gene in SIMA9 microglia 
was achieved using Dharmacon (Lafayette, CO) Accell SMARTpool siRNA 
(product E-043246-00-0050) or cells were treated with non-targeting siRNA 
(product D-001910-01-50) as a control. siRNA was utilized by combining the 
Accell siRNA with Accell delivery media per manufacturer’s instructions and cells 
were treated with a working concentration of 1µM siRNA for 6 days. After 3 days 
of treatment (72 hours), siRNA containing media was supplemented 1:1 with 
normal DMEM/F12 with 10% FBS. SIMA9 cell protein was harvested on day 7 for 
western blot analysis. 
APP Plasmids and Transfections 
 pCAX APP 751 and pCAX APP 695 were a gift from Dennis Selkoe & 
Tracy Young-Pearse and are available from Addgene as plasmids 30138 and 
30137 (Young-Pearse et al., 2007). Plasmids were prepared using Qiagen 
Endofree Plasmid Giga Kit (product 12391). Primary astrocyte cultures were 
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transfected using lipofectamine 3000 (ThermoFisher Scientific) as per 
manufacturer’s instructions. 
Mouse Neuron Primary Culture 
 Neurons were cultured from WT and APP-/- embryonic brain tissue on 
embryonic day 16. Pregnant mothers were killed using CO2 and cervical 
dislocation. Embryos were harvested and brains placed into sterile dissection 
media (.5mM EDTA, 100 µM EGTA, 5.5 mM glucose, in PBS).  Meninges were 
removed and both cortices were harvested and minced in dissection media then 
added to 0.25% trypsin. Tissue was digested for 20 minutes at 37 degrees 
centigrade. Digestion was terminated by adding 10 mL DMEM/F12 containing 
10% FBS. The cells were allowed to settle in the bottom of the pipette tip and 
then added to 10 mL of neurobasal media supplemented with B27 and L-
Glutamine, then triturated approximately 20 times.  Cells were cultured in 6 well 
plates coated overnight with poly-L-lysine. Neuron cultures were grown at 37 
degrees in 5% CO2.  
Mouse Microglia and Astrocyte Primary Culture 
 Microglia and astrocyte cultures were grown from 1 day old WT and APP-
/- neonate pups. Meninges were removed from pups and cortical tissue was 
harvested in dissection media (.5mM EDTA, 100 µM EGTA, 5.5 mM glucose, in 
PBS) on ice. Cortices were then digested in trypsin for 15 minutes. Digestion was 
terminated using DMEM/F12 media containing 10% FBS. Each individual’s 
cortical tissue was cultured separately in a T75 flask with 20 mL of DMEM/F12 
supplemented with 10% FBS. Media was supplanted on day two and replaced 
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after 1 week. After two weeks of culture, microglia were separated from 
astrocytes by shaking flasks at 200 RPM for 45 minutes to 1 hour. Supernatant 
was collected for microglia, while astrocytes adhered to flask and were removed 
with trypsin. Astrocytes were then passaged and cultured on 6 well plates for 
experiments.  
IDE Activity Assays 
 The IDE activity assays were purchased from AnaSpec (Fremont, CA) 
(Catalog # AS-72231). The IDE activity assay utilizes a FRET substrate, which 
emits increased fluorescence when cleaved by IDE. Hippocampus tissue, liver, 
and gastrocnemius muscle was collected on ice from WT and APP-/- animals. 
Our preliminary experiments utilizing this assay suggested that IDE enzyme 
activity is negatively affected by sonication. Tissue was homogenized on ice in 
assay buffer using an automated mortar and pestle. 50uL of each individual 
animal’s tissue homogenate was loaded into a well of a 96 well plate containing 
50uL of substrate solution. The fluorescent intensity was measured on a 
fluorescent plate reader (BioTek) using an excitation of 485 nm and emission of 
528 nm at 5 minute increments. Fluorescent units measured were converted to 
concentrations of 5-FAM. The protein concentration of each tissue homogenate 
was determined using the Bradford method and 5-FAM concentrations were 
normalized to total protein in each sample. Total IDE activity in each sample was 
calculated using the formula (Final Substrate Concentration – Initial Substrate 
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Concentration / Time x Volume) x Dilution factor described by Kurauti et al. and 
normalized to each samples total protein. 
Hippocampus Synaptosome Preparation and Stimulation 
 Synaptosomal insulin responsiveness was evaluated by ex vivo 
stimulation of isolated synaptosomal preparations as previously described 
(Franklin & Taglialatela, 2016). Briefly, frozen WT and APP−/− mouse 
hippocampi were homogenized using SynPER reagent (Thermo Scientific) with 1 
% protease inhibitor cocktail and phosphatase inhibitor cocktail and centrifuged 
at 1230 ×g for 10 min at 4°C. The supernatant was collected and centrifuged 
once more at 15000 ×g for 20 min at 4°C. The pellet was resuspended in a 
physiological buffer, HEPES-buffered Krebs-like HBK buffer (143-mM NaCl, 4.7-
mM KCl, 1.3-mM MgSO4, 1.2-mM CaCl2, 20-mM HEPES, 0.1-mM NaH2PO4, 
and 10-mM D-glucose, pH 7.4) and aliquoted into tubes of equal protein for 
unstimulated and insulin-stimulated samples. All tubes received 8 mM ATP and 
insulin stimulation was performed with 10nM or 200nM of diluted U-100 insulin. 
All tubes were incubated at 37 °C for 15 min. Samples were pelleted at 10000 ×g 
for 10 min at 4°C and resuspended in 1× RIPA (75-mM NaCl, 25-mM Na2PO4, 
1-mM EDTA, 0.5% NP-40, and 0.5% TritonX-100) plus 1%  protease inhibitor 
cocktail and phosphatase inhibitor cocktail. The bicinchoninic acid assay method 
was used to prepare samples of equal protein concentration for WES capillary 
Western blot technology (ProteinSimple). Data was collected using the area 
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under peaks for the specified proteins and analysis performed using a Student’s 
t-test. 
Statistical Analysis 
 Statistical analysis was performed using SigmaPlot 12.0 software. Values 
were averaged +/-SD and statistical significance was determined via one-way 
ANOVA, two-way ANOVA or t-test, as appropriate. In the case of statistical 
significance, the Turkey-Kramer post hoc test or Holm-Sidak multiple pair-wise 
comparisons were used where applicable. 
 The difference in the mean relative IDE mRNA expression values for WT 
and APP-/- was statistically analyzed by performing unpaired t-test with Welch 
correction factor using GraphPad Prism 7.03 software (GraphPad Software, Inc., 
La Jolla, CA).  P values less than 0.05 were considered statistically significant. 
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CHAPTER III 
RESULTS 
Study 1 – Amyloid Precursor Protein in the Endocrine Pancreas 
Introduction 
 Several lines of evidence indicate that metabolic dysfunction, insulin 
resistance and perturbations in cerebral glucose utilization may play a critical role 
in the disease process (Bedse, Di Domenico, Serviddio, & Cassano, 2015; 
Biessels, Staekenborg, Brunner, Brayne, & Scheltens, 2006; De Felice & 
Ferreira, 2014; de la Monte, 2014; Hoyer, 1991). Type 2 diabetes, or insulin 
resistance, is reported to be a risk factor for developing dementia and evidence 
suggests insulin signaling dysfunction occurs in the brains of AD patients (Crane 
et al., 2013; Talbot et al., 2012).  
 One protein thought to be critical in the development of AD is Aβ, a self-
aggregating peptide cleaved from the larger amyloid precursor protein (APP) 
(Goldgaber, Lerman, McBride, Saffiotti, & Gajdusek, 1987; Selkoe et al., 1988). 
APP is a single pass transmembrane protein of uncertain function highly 
expressed in the CNS and detectable in many other cell types (Arai et al., 1991; 
Konig et al., 1992; Schlossmacher et al., 1992). It is cleaved by proteases such 
as beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) and gamma 
secretase to release N-terminal fragments (sAPPα and sAPPβ) and varying size 
Aβ fragments (Aβ 1-40 and Aβ 1-42). Much of the research focused on APP 
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biology has been in the context of Aβ plaque deposition in the central nervous 
system. However, it is known that higher molecular weight isoforms of APP are 
present in many peripheral organs (Selkoe et al., 1988). Our recent work has 
focused on characterizing APP expression and function in several peripheral 
tissues including intestinal and adipose tissue (Puig & Combs, 2013; Puig, 
Floden, et al., 2012; Puig, Lutz, et al., 2015; Puig, Swigost, et al., 2012; Sondag 
& Combs, 2010).  
 The pancreas has an essential role in the regulation of blood glucose 
levels, primarily through the secretion of the hormone insulin from pancreatic 
β cells. Pancreatic dysfunction is a well-known consequence of both type 1 and 
type 2 diabetes (Ashcroft & Rorsman, 2012). Numerous studies in both primates 
and mice suggest that damaging or stressing the endocrine pancreas may 
promote changes in the central nervous system associated with the 
pathogenesis of AD (Ho et al., 2004; Julien et al., 2010; Morales-Corraliza et al., 
2016; Takeda et al., 2010; X. Wang et al., 2010). Injections of insulin into a 
transgenic mouse model of AD have been shown to improve the memory of 
these mice as well as alter circulating concentrations of Aβ (Vandal et al., 2014). 
Administration of insulin into the brain intranasally is being explored as a 
cognitive enhancing therapeutic strategy in patients with AD (Claxton et al., 2015; 
Holscher, 2014; Reger et al., 2008).  
 Like Alzheimer’s disease, diabetes has its own plaque pathology, in which 
the self-aggregating peptide amylin, or IAPP, is co-secreted with insulin and 
damages pancreatic islets (Lorenzo, Razzaboni, Weir, & Yankner, 1994; 
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Westermark, Wilander, Westermark, & Johnson, 1987). Whether Aβ itself 
influences pancreatic IAPP aggregation through cross-seeding, or injures islets 
independently of IAPP remains uncertain. There are conflicting reports of the 
detection of amyloid beta within human islets (Miklossy et al., 2010; Oskarsson et 
al., 2015). Increased levels of Aβ or Aβ aggregates have been detected within 
the pancreas of some transgenic mouse models of AD (Shoji et al., 1998; Shoji 
et al., 2000; Vandal et al., 2015). 
 There is evidence that suggests that the endogenous functions of APP 
may be linked to the regulation of insulin secretion and signaling or whole body 
metabolism.  The detection of APP has been reported in the exocrine and 
endocrine pancreas by immunohistochemistry and in-situ hybridization, 
respectively (Beer, Masters, & Beyreuther, 1995; Figueroa, Shi, Gardell, & 
Austin, 2001). Additionally, a rigorous analysis of mice lacking APP (APP-/-) 
and/or the related APLP2 gene shows changes in circulating blood glucose 
concentrations (Needham et al., 2008). Another report has suggested APP may 
directly regulate the process of insulin secretion from pancreatic islets (Tu et al., 
2012).  In this study we examine murine and human pancreatic tissue to test the 
hypothesis that APP or Aβ play a role in pancreatic function or pathophysiology 
respectively. 
APP was Expressed within the Endocrine Pancreas 
 To begin studying APP in the pancreas, we examined whole pancreatic 
tissue collected from two month old wild type C57B6 (WT) , APP-/-, and 
APP/PS1 mice. The APP-/- animals have the APP gene knocked out in all 
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tissues. APP/PS1 mice overexpress both human APP and the γ-secretase 
complex protein Presenilin-1 protein under the control of the prion promoter. This 
leads to high transgene expression in the central nervous system and results in 
Aβ plaque deposition in the brain with age. Pancreatic protein lysates were 
resolved by 10% SDS-PAGE and immunoblotted to compare expression of APP 
(Fig 1A). APP was detected in wild type pancreas, absent in APP-/- tissue, and 
overexpressed in APP/PS1 mice. However, the human APP695 transgene 
migrated at an apparent lower molecular weight than endogenous mouse APP, 
consistent with reported expression of higher molecular weight isoforms in 
peripheral tissues (Selkoe et al., 1988).  
 In order to determine which cell types were expressing APP, 
immunohistochemistry was next performed. Pancreas from both two and twelve 
month old WT, APP-/- and APP/PS1 mice was serial sectioned and stained using 
antibodies against the c-terminus of APP (Fig 1B). Endogenous APP 
immunoreactivity localized to both endocrine and exocrine pancreas, with clear 
immunoreactivity in pancreatic islets at 12 months of age. APP immunoreactivity 
in the APP/PS1 transgenic mice robustly localized to islets at either age.  
Following our investigation of murine tissue, we determined whether human 
pancreatic islets also expressed APP. Immunohistochemistry was performed on 
healthy, type 2 diabetes, and cancerous human pancreatic tissue using 
antibodies directed against  the c-terminus of APP. Similar to the mouse tissue 
findings, we observed clear APP immunoreactivity within the endocrine pancreas 
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Figure 1. Amyloid precursor protein was detected in mouse and human 
pancreas including islets of Langerhans.  
 
(A) Whole pancreas was collected from C57BL/6 (WT), APP-/-, and 
APP/PS1 mice (n=7) and lysed in RIPA buffer. 20 µg of protein was 
resolved by 10% SDS-PAGE and western blotted using anti-APP 
(Y188) antibody or anti-GAPDH antibody as a loading control. 
Normalized optical density was averaged +/- SD, *p<0.05.  
 
(B) Pancreas was harvested from C57BL/6 (WT), APP/PS1, and 
APP-/- at 2 months (n=7) and 12 months (n=4) of age. Tissue was 
fixed in 4% paraformaldehyde and cryosectioned into 10 µm serial 
sections. Immunohistochemistry was performed using anti-APP 
(Y188) antibody. Vector VIP was used as the chromogen.  
 
(C) Immunohistochemistry was performed on human pancreatic 
tissue. Pancreas from a healthy 77 year old male donor, 68 year 
old male type 2 diabetic donor and a 66 year old male with 
pancreatic adenocarcinoma was probed using anti-APP antibody 
(Y188) with vector VIP used as the chromogen.  
 
(D) Representative western blot of protein lysates from cultured 
pancreatic islets from WT, APP-/-, and APP/PS1 mice. Islet protein 
was resolved by 10% SDS-PAGE, transferred to PVDF, and 
immunoblotted using anti-APP antibody (Y188). Islets from a 
healthy 55 year old male donor were cultured then lysed in RIPA 
buffer and resolved using 10% SDS-PAGE then transferred to 
PVDF membrane and western blotted using anti-APP antibody, 
22C11. 
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of all three tissue types (Fig 1C). Pancreatic adenocarcinoma samples showed 
particularly robust APP islet immunoreactivity (Fig 1C, Fig 2). This is in 
agreement with a number of studies demonstrating upregulated APP in 
pancreatic cancer where it may play a role in the disease process (Hansel et al., 
2003; Woods & Padmanabhan, 2013). 
 
 
 
Figure 2.  APP immunoreactivity was increased in pancreatic 
adenocarcinoma. Cryosections (10µm) from human healthy 
pancreas and pancreatic adenocarcinoma were immunostained for 
APP and insulin. Alexa Fluor 488 and 594 conjugated secondary 
antibodies were used for visualization. 
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 The islet enriched APP immunoreactivity was validated by western blot 
analysis from both murine and human islet cultures. Islets grown from WT, APP-
/-, and APP/PS1 mice demonstrated the expected increase in APP expression in 
the APP/PS1 line with no detectable APP in the APP-/- mice (Fig 1D). Human 
islet cultures also demonstrated robust APP levels via western blot analysis  
(Fig 1D). 
 Pancreatic islets are primarily composed of insulin producing β cells. To 
determine whether APP localized within these specialized cells we next 
examined pancreas from the APP/PS1 mouse by immunofluorescence using 
primary antibodies against APP and insulin. APP immunoreactivity was highly 
localized to the insulin producing cells in the APP/PS1 mice (Fig 3A) Using the 
same approach, we confirmed that APP localized to β cells of the human 
pancreas (Fig 3B). 
Pancreatic APP was Not Processed to Aβ 
 The presence of Aβ containing plaques has been reported in the pancreas 
of some strains of transgenic mice although evidence of Aβ in human pancreas is 
conflicting (Miklossy et al., 2010; Oskarsson et al., 2015). To determine whether 
Aβ was present in our transgenic samples we utilized two methods, ELISA and 
immunohistochemistry, to detect Aβ in mouse and human pancreas. Human Aβ 
1-40 and 1-42 was quantified by ELISA from WT, APP-/- and APP/PS1 
hippocampus, pancreas and primary islet culture lysates from twelve month old 
animals (Fig 4A). Interestingly, while high concentrations of human Aβ were 
detectable in the brain lysates of APP/PS1 transgenic animals, we did not detect 
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Figure 3.  Amyloid precursor protein was detectable in the insulin producing 
β cells of the human pancreas and the APP/PS1 mouse. Pancreatic 
APP was not processed to Aβ. Immunofluorescent staining was 
performed using (A) APP/PS1 transgenic mouse and (B) human 
tissue cryosections (10µm). Anti-APP (Y188) and insulin primary 
antibodies with Alexa Flour 488 and Alexa Flour 594 fluorophore 
conjugated secondary antibodies were used for visualization with 
DAPI counterstain.
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Figure 4. Aβ was not detectable in mouse pancreas by 
immunohistochemistry or ELISA.  
(A) Mouse pancreas and hippocampus tissue was lysed in RIPA 
buffer (n=4/strain), while islets (n=6/strain) were pelleted and lysed 
in Triton X-100 buffer to yield detergent soluble Aβ extract. Extract 
was used to quantify both human Aβ 1-40 and human Aβ 1-42 by 
ELISA. APP-/- animals served as a negative control to measure the 
background of the assay. Data is expressed as mean values +/-SD, 
*p<0.05 from WT.  
(B) Immunohistochemistry was performed on 10µm cryosections of 
WT, APP-/-, and APP/PS1 murine pancreas as well as human 
healthy control, type 2 diabetes (T2D), and adenocarcinoma 
pancreas tissue. Anti-Aβ antibody (4G8) was used with Vector VIP 
as the chromogen.
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a significant increase in Aβ in the pancreas or islet lysate of these animals. 
Taken together, these data suggest that APP is processed by alternative 
mechanisms in the pancreas as compared to brain. 
 To further investigate the possibility of pancreatic Aβ production, we 
utilized immunohistochemistry to stain for Aβ. Since we and others have 
previously observed that the APP/PS1 line accumulates brain Aβ deposits in an 
age dependent manner (Gordon et al., 2002; Manocha et al., 2016), WT and 
transgenic mouse pancreas were immunostained to detect Aβ at two and twelve 
months of age (Fig 4B). A faint amount of immunoreactivity was observed in 
12 month old APP/PS1 islets relative to the APP-/- and WT mice likely due to the 
anti-Aβ antibody, 4G8, cross-reacting with full length APP. However, there were 
clearly no distinct signs of Aβ plaque deposition in either the two or twelve month 
old mouse pancreas. We also examined healthy, type 2 diabetes, and 
adenocarcinoma human pancreas tissue for Aβ immunoreactivity as well as for 
nonspecific amyloids by thioflavin staining (Fig 4B, Fig 5). While thioflavin S 
stained several areas of both healthy and type two diabetic pancreas, no 
detectable Aβ plaque-like deposits were observed although some scattered 
puncta which may correspond to Aβ or sAPP were noted in all conditions, 
including within pancreatic islets. Following these negative results, we sought to 
determine if the methodology we employed was sufficient to detect amyloid 
deposits. We performed immunostaining for Aβ in addition to thioflavin S staining 
in 12 month WT and APP/PS1 mouse brain tissue sections (Fig 5). As expected, 
APP/PS1 brains showed abundant plaque deposition using both methods without 
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detectable plaques in WT brains (Fig 5) in contrast to a clear lack of any plaque-
like deposits in the pancreas (Fig 4B). 
 
 
 
 
Figure 5.  Thioflavin staining and Aβ immunohistochemistry in human 
pancreatic tissue and mouse brains. Cryosections (10µm) of 
healthy human pancreas and type 2 diabetic pancreas or WT and 
APP/PS1 brain tissue sections (40 µm) were immunostained for Aβ 
or stained with thioflavin S. Vector VIP was used as the 
chromogen. 
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APP/PS1 Mice Showed no Differences in Glucose Tolerance Testing or  
Pancreatic Insulin Levels but had Significantly Decreased  
Pancreatic Glucagon Compared to WT and APP-/- Mice. 
 
 An essential function of the pancreas is to regulate blood glucose levels. 
In order to test if differences in pancreatic islet APP content caused changes in 
whole body glucose tolerance we subjected WT and transgenic animals to 2g/kg 
glucose challenge by oral gavage. Blood glucose measurements were taken 
from tail clipping after four hours of fasting and at 15, 30, 60 and 120 minutes 
after glucose challenge (Fig 6A, B). Surprisingly, no differences were observed 
across genotypes. In addition to assessing glucose tolerance, we also 
homogenized whole pancreas from 2 month old animals and assessed their 
insulin and glucagon content by ELISA (Fig 6C, D). Glucagon concentrations 
from APP/PS1 pancreas were significantly lower than WT and APP-/- mice 
although no changes in insulin content were detected across genotypes. Based 
upon the glucagon differences, APP/PS1 pancreas tissue was fluorescently 
double labeled with anti-APP and glucagon antibodies. Although there were 
relatively few glucagon immunoreactive cells it was clear that they colocalized 
with APP immunoreactivity suggesting that transgene expression alters the 
biology of these cells (Fig 7).
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Figure 6.  No difference in glucose tolerance or pancreatic insulin content was 
observed in APP-/- and APP/PS1 mice, but whole pancreas 
glucagon content was reduced in APP/PS1 mice. 2 month old WT, 
APP-/-, and APP/PS1 mice were subjected to glucose tolerance 
testing. Prior to testing, mice were fasted four hours and then 
received 2g/kg glucose by oral gavage.  
(A) Blood glucose was measured at intervals by blood glucose 
meter (n=4-7).  
(B) The area under the curve (AUC) from glucose tolerance testing 
of each mouse was measured and the results from each strain are 
graphed. Each strain was normalized to the mean AUC of the WT 
strain. Whole mouse pancreas was lysed using RIPA buffer.  
(C) Insulin (n=6-7) and  
(D) glucagon (n=6-7) content were assessed by ELISA. Data is 
shown as mean values +/-SD, *p<0.05.
 51 
 
Figure 7.  APP was present in glucagon producing cells in the APP/PS1 
mouse. Cryosections (10µm) of APP/PS1 mouse pancreas were 
immunostained for APP and glucagon. Alexa Fluor 488 and 594 
conjugated secondary antibodies were used for visualization. 
 
 
APP Expression Modulated Pancreatic BACE2, GLUT4, and IDE  
Levels in the Transgenic Mice. 
 
 To better understand the contribution of APP expression to pancreatic 
physiology, we quantified protein levels from homogenized murine pancreas of 
WT and transgenic animals by western blot with a particular focus on proteins 
involved in insulin signaling, glucose uptake and Aβ degradation (Fig 8). 
Although no changes in protein levels of the glucose transporters GLUT1, 
GLUT2, or GLUT3 were observed across genotypes, protein levels of GLUT4 
were significantly elevated in APP-/- mice compared to WT, and APP/PS1 mice. 
No differences in insulin receptor (IR), pAkt or pGSK3β levels were observed. 
Similarly, total protein levels of zinc transporter 8 (ZNT8) did not differ across  
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Figure 8.  Differences in 2 month old mouse pancreatic BACE2, IDE and 
GLUT4 were observed by western blot. Whole pancreas from WT, 
APP-/-, and APP/PS1 mice was lysed in RIPA buffer and resolved 
using 10% SDS-PAGE. Protein was transferred to PVDF 
membrane and western blotted for multiple proteins using GAPDH 
as a loading control. Optical density was measured and normalized 
to mean WT optical density (n=7). Data is expressed as mean 
values +/-SD, *p<0.05. 
 
 
species. BACE2 has been suggested to both interact with APP in vitro as an α-
secretase and play a role in pancreatic insulin secretion through the cleavage of 
its substrate, TMEM27 (Esterhazy et al., 2011; Yan, Munzner, Shuck, & 
Bienkowski, 2001). We assessed BACE2 protein levels using an antibody 
against an amino acid sequence within the prodomain of BACE2 that is not found 
in BACE1 (B. D. Bennett et al., 2000). Strikingly, total protein levels of BACE2 
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were significantly reduced in APP-/- and APP/PS1 compared to WT indicating 
that APP may influence the expression or activity of BACE2 in the pancreas. 
Since both Aβ and insulin are degraded by a common enzyme, insulin degrading 
enzyme (IDE) (Qiu et al., 1998), we quantified IDE protein levels to observe a 
significant increase in APP-/- mice compared to all other genotypes. We also 
quantified protein levels of another Aß degrading enzyme, neprilysin, but 
detected no differences across genotypes. This suggested that APP has a role in 
regulating the expression of GLUT4, IDE and BACE2 in the pancreas. 
BACE2 Immunoreactivity was Localized to Islet Periphery  
with Decreased Immunoreactivity in APP/PS1 Mice With  
no Concomitant Increase in Aβ Immunoreactivity. 
 
 Following our observation of changes in pancreatic BACE2 and IDE 
protein levels, we performed immunohistochemistry on 2 month old WT and 
transgenic mouse pancreatic serial sections to determine where changes in 
protein expression localized (Fig 9A). Increased immunoreactivity for IDE was 
observed in APP-/- tissue, with the higher levels of IDE observed in the acinar 
tissue of the pancreas. Immunohistochemistry for BACE2 using antibodies 
directed against the N-terminal prosequence revealed BACE2 expression within 
the endocrine pancreas, with the highest levels of immunoreactivity at the 
periphery of islets. In agreement with the western blots, BACE2 immunoreactivity 
was notably less robust in APP/PS1 mice compared to WT. To validate this 
pattern of BACE2 tissue expression and further investigate APP processing 
within pancreatic islets, we performed immunohistochemistry on 12 month old 
WT and transgenic mouse pancreas sections using primary antibodies against 
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BACE2, IAPP, CD68, Aβ Glucagon (Fig 9B, Fig 10) Immunohistochemistry for 
BACE2 revealed a similar pattern of protein expression at 12 months of age as 
was observed at 2 months, with the highest levels of BACE2 detected at the 
periphery of the islets. We further validated our BACE2 immunohistochemistry 
results by performed peptide blocking studies in mouse tissue to demonstrate the 
specificity of the BACE2 islet staining (Fig 10). Antibody pre-incubation with the 
BACE2 epitope blocking peptide completely abolished islet BACE2 staining at 
the islet periphery demonstrating our immunohistochemistry results are specific 
 
 
 
Figure 9.  Immunohistochemistry of 2 and 12 month old mouse pancreas.  
(A) Immunohistochemistry was performed on WT, APP-/-, and 
APP/PS1 mouse 2 month old 10µm pancreas cryosections using 
primary antibodies against IDE and BACE2 (n=7). Tissue was fixed 
with 4% paraformaldehyde and Vector VIP chromogen was used as 
the chromogen. (B) Immunohistochemistry was performed on 
12 month old murine 10µm pancreas cryosections (n=4). Primary 
antibodies against amylin/IAPP, BACE2, CD68, Aβ oligomers 
(MOAB-2) and Aβ were utilized to detect proteins. Vector VIP was 
used as the chromogen. 
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Figure 10.  BACE2 immunohistochemistry with epitope blocking peptide 
control and glucagon immunohistochemistry with optical density 
quantitation in mouse tissue.  
(A) Cryosections (10µm) of WT and transgenic mouse pancreas 
were immunostained for BACE2 in the presence or absence of a 
BACE2 epitope blocking peptide. Vector VIP was used as the 
chromogen. Densitometric analysis of BACE2 islet immunostaining 
was conducted in 12 month old mice (n=8). Staining intensity 
values were normalized to WT levels and averaged +/-SD, *p<0.05. 
(B) Cryosections (10µm) of WT and transgenic mouse pancreas 
were immunostained for glucagon with Vector VIP as the 
chromogen. Densitometric analysis of glucagon islet 
immunostaining was conducted in 12 month old mice (n=5-6). 
Staining intensity values were normalized to WT levels and 
averaged +/-SD, *p<0.05. 
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to the BACE2 epitope. We also quantified the intensity of BACE2 and glucagon 
immunoreactivity in mouse islets and observed significantly less BACE2 and 
glucagon staining in APP/PS1 mouse islets (Fig 10). No differences in 
IAPP/amylin aggregation were observed across mouse genotypes, which is as 
expected as mouse amylin is not known to form amyloid plaques. No Aβ plaque-
like structures were detectable using antibodies against monomeric or oligomeric 
Aβ. Staining with anti-CD68 antibody to detect macrophages did not reveal any 
differences in islet macrophage infiltration suggesting local overexpression of 
APP within islets did not result in local Aβ-mediated immune activation as is 
known to occur in the central nervous system (Dhawan, Floden, & Combs, 2012; 
Jimenez et al., 2008). As expected, mouse glucagon was localized primarily at 
the islet periphery.  
 
 
 57 
Immunohistochemistry for BACE2 Demonstrated Differential  
BACE2 Localization in α and β Cells in Both  
Mouse and Human Tissue. 
 
 To determine the identity of the pancreatic islet cells stained positive for 
BACE2, we performed immunofluorescent double labeling of tissue from WT 2 
month old animals for BACE2 and either insulin or glucagon (Fig 11). 
Surprisingly, BACE2 immunoreactivity was highest in cells staining positive for 
glucagon suggesting BACE2 may be differentially active or expressed in 
pancreatic α compared to β cells. The staining of α cells at the periphery of the 
islet is consistent with the known anatomical organization of murine pancreatic 
islets of Langerhans (Cabrera et al., 2006). Using this approach, we stained WT, 
APP-/-, and APP/PS1 mouse pancreas for both BACE2 and insulin, and obtained 
complimentary results indicating the BACE2 enzyme localized within the islets 
and was more highly immunoreactive outside the insulin producing cells at the 
periphery of the islets (Fig 12). We then co-labeled human pancreatic tissue for 
BACE2 and glucagon in the absence or presence of the BACE2 epitope blocking 
peptide to determine if BACE2 was also present in human α cells (Fig 11). 
Interestingly, we again observed robust BACE2 immunoreactivity in glucagon 
positive cells, indicating this pattern of BACE2 expression is conserved across 
mouse and human α cells. Pre-incubation with the BACE2 epitope blocking 
peptide eliminated BACE2 immunoreactivity in α cells, indicating this antibody 
staining was specific to the BACE2 protein epitope.
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Figure 11.  BACE2 was present in glucagon positive cells. 
Immunohistochemistry was performed on (A) WT mouse and (B) 
human 10µm pancreas cryosections using antibodies against 
BACE2 and insulin or glucagon with or without pre-incubation with 
BACE2 epitope blocking peptide. Fluorescent secondary antibodies 
were used for visualization (anti-rabbit Alexa-Fluor 488 and anti-
mouse Alexa Fluor 594). DAPI staining was used to visualize cell 
nuclei.  
 
 
 
 
Figure 12. BACE2 immunoreactivity in wild type and transgenic mouse islets. 
Cryosections (10µm) of WT and transgenic mouse pancreas were 
immunostained for BACE2 and insulin. Alexa Fluor 488 and 594 
conjugated secondary antibodies were used for visualization with a 
DAPI counterstain. 
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Primary Murine Islet Cultures Showed Significant Differences  
in APP and IDE Content. 
 
 Only a small fraction of the pancreas is composed of hormone secreting 
endocrine cells. To determine if protein differences observed in the whole 
pancreas lysate were due in part to differences in pancreatic islets, we cultured 
pancreatic islets isolated from WT, APP-/-, and APP/PS1 animals. We cultured 
these islets for 24 hours and selected healthy islets of similar size for lysing and 
western blot analysis (Fig 13). We examined islet lysate for differences in APP, 
IDE, GLUT4 and BACE2 as differences in the levels of these proteins were 
observed in whole pancreas lysate. GAPDH was utilized as a loading control. As 
expected, APP was not detectable in APP-/- islets while APP/PS1 islets had high 
levels of APP. Surprisingly, like our whole pancreas extracts, IDE was 
significantly increased in APP-/- islets compared to WT. We were unable to 
detect GLUT4 in islet lysates. Islet BACE2 protein levels were not significantly 
different in transgenic animals compared to wild type controls, in contrast to our 
immunostaining results. One possibility for this discrepancy is perhaps due to 
loss of peripheral islet cell integrity during the isolation or culture conditions we 
employed suggesting that further optimization is required in future work. 
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Figure 13.  Western blots of 12 month old mouse primary islet cultures. WT, 
APP-/-, and APP/PS1 pancreatic islets (n=3) were cultured 
overnight and the next day 50 islets from each animal were 
selected, pelleted, and lysed in RIPA buffer. Protein lysate was 
resolved by 10% SDS-PAGE then transferred to PVDF membranes 
and western blotted with antibodies against APP (Y188), IDE, 
GLUT4, and BACE2. Anti-GAPDH was used as a loading control. 
Optical density was measured for IDE and BACE2 and was 
normalized to WT optical density. Data is expressed as mean 
values +/-SD, *p<0.05. 
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APP was Processed by α-secretase Activity in Primary  
Islet Cultures and Recombinant sAPP Potentiated Islet Insulin  
but not Glucagon Secretion. 
 
 The presence of BACE2, as well as the lack of detectable Aβ, suggested 
that pancreatic APP was processed by a non-amyloidgenic pathway. It is known 
that sAPP is detectable in the conditioned media of cell cultures from a number 
of cell types (Weidemann et al., 1989). To determine if processing of pancreatic 
APP resulted in the release of sAPP into conditioned media, we grew primary 
cultures of both mouse and human pancreatic islets and collected the cells and 
conditioned media after 24 hours for western blot analysis (Fig 14A). Both murine 
and human mutant APP were processed through the α-secretase pathway 
resulting in the release of sAPP into culture media, including the human mutant 
APP expressed in APP/PS1 islets. Human sAPPα from APP/PS1 islets was 
detected using the 6E10 monoclonal antibody, which is has been demonstrated 
to bind human sAPPα (Bailey et al., 2008). 
To better understand whether secreted sAPPα may have autocrine 
effects, we assessed insulin and glucagon secretion from primary cultures of 
isolated islets. A glucose stimulated insulin secretion (GSIS) assay demonstrated 
significantly attenuated insulin secretion from APP-/- islets compared to WT and 
APP/PS1 while APP/PS1 islets had significantly higher insulin secretion 
compared to both WT and APP-/- cultures (Fig 14B). In order to determine 
whether the differences in insulin secretion could be related to sAPPα, WT islet 
cultures were stimulated with recombinant sAPPα during the GSIS assay. 
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Figure 14.  sAPP was released from primary murine and human islet cultures 
and recombinant sAPPα potentiated islet insulin secretion during 
glucose stimulated insulin secretion assay.  
 
(A) Primary islet cultures from WT, APP-/-, and APP/PS1 mice 
were grown for 24 hours. Conditioned media was collected and 
protein content was assessed by western blot using antibodies 
against N-terminal APP. 22C11 detects both mouse and human 
APP while 6E10 is specific to human APP and detects sAPPα. 
Human islets were cultured for 24 hours and both conditioned 
media collected for analysis by western blot using anti N-terminal 
APP antibody (22C11).  
 
(B) Primary cultures of mouse islets were assessed for differences 
in insulin and glucagon secretion at 5mM glucose. Wild type islets 
were stimulated with 10 nM recombinant human sAPPα and 
supernatant was collected for insulin (n=8) and glucagon (n=4) 
ELISA. Insulin secretion data from multiple sAPP stimulation 
experiments were pooled by normalizing to the mean of the 
unstimulated control from each experiment.  
 
(C) The MIN6 insulin secreting cell line was grown as pseudo-islets 
and was stimulated with 0, 1nM, or 10nM recombinant sAPPα in 
GSIS assay at either 3.7mM or 16.7 mM glucose (n=6-8/condition). 
Data is expressed as the mean +/- SD, *p<0.05.   
 
(D) Human islets were treated with 10 nM recombinant sAPPα 
during the GSIS assay in 3.7, 10, and 16.7 mM glucose. After one 
hour of treatment, islet insulin secreted into the supernatant was 
assessed by ELISA. Data was pooled from five donors and 
normalized to basal insulin secretion at 3.7 mM. Data is expressed 
as the mean +/- SD, *p<0.05. 1µM forskolin was used with 16.7 mM 
glucose to potentiate insulin secretion as a positive control. 
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In these studies, we utilized 10 nM sAPPα for stimulations as this concentration 
has been shown to initiate signaling events in neuronal cells and is above the 
estimated EC50 of 2.3nM (Jimenez et al., 2011).  Stimulation with sAPPα 
resulted in a significant but modest potentiation of islet insulin but not glucagon 
secretion (Fig 14B).  
 This suggested that differences in basal insulin secretion from primary 
cultures of islets across genotype may be due, in part, to autocrine stimulation 
with sAPPα. It also suggests that sAPPα has a role particularly in insulin biology 
of pancreatic islets or may support islet phenotype and survival in vitro.  
 Following our observation that sAPPα potentiates insulin secretion in 
cultures of primary mouse islets, we sought to further validate this finding by 
utilizing the MIN6 mouse β-cell line to test the effect of different doses of sAPPα 
and different concentrations of glucose on insulin secretion from MIN6 
pseudoislets (Fig 14C). Similar to our primary islet cultures, we observed that 
treatment with sAPPα modestly but significantly potentiated insulin secretion from 
MIN6 pseudoislets at 16.7mM glucose concentration. This effect was dose 
dependent, with 10 nM but not 1 nM recombinant sAPPα having a significant 
effect.  
 In order to further validate the findings from the mouse islets and MIN6 
cells, we performed similar GSIS assays on human donor islets. Treatment of 
human islets with 10 nM recombinant sAPPα during GSIS assays demonstrated 
a significant potentiation of insulin secretion using a range of glucose 
concentrations (Fig 14D). 
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CHAPTER IV 
RESULTS 
Study 2 – Amyloid Precursor Protein and Insulin Degrading Enzyme 
Introduction 
 Mounting evidence suggests that perturbations in brain metabolism and 
insulin signaling play a role in the pathology of Alzheimer’s disease (AD) (Harris 
et al., 2016; Hoyer, 1991; Macauley et al., 2015; Mosconi et al., 2006; Talbot et 
al., 2012) Histologically, AD is characterized in part by the robust accumulation of 
extracellular “plaque” aggregates of the Aβ peptide in central nervous system 
(Selkoe & Hardy, 2016). Aβ is generated in the brain by the enzymatic cleavage 
of the much larger Amyloid precursor protein (APP). Amyloid precursor protein or 
APP is a transmembrane glycoprotein encoded on the 21st chromosome in 
humans (Blanquet et al., 1987; Robakis et al., 1987). APP is part of a three 
member family of proteins which also includes APLP1 and APLP2 (U. C. Muller & 
Zheng, 2012). While expression of APLP1 is largely restricted to the central 
nervous system, both APP and APLP2 are expressed ubiquitously and can be 
detected in a variety tissues (Lorent et al., 1995). Of this protein family, only APP 
generates the Aβ peptide. Interestingly, the APP family of proteins seems to be 
required for life, or is at least critical for normal animal development. Knockout of 
APP and APLP2 genes in mice has been shown to be postnatally lethal, as is 
knockout of both APLP1 and APLP2 (Heber et al., 2000). Deletion of just the 
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APP gene confers a more benign phenotype, including reduced animal body 
weight and organ size, changes in grip strength and broad changes in 
metabolism (Puig et al., 2017; Zheng et al., 1995). Mouse knockouts of APLP1 
have also been studied and show similar reductions in animal body weight 
(Heber et al., 2000). The APP gene is widely conserved among other species, 
suggesting it performs important or advantageous biological functions (Tharp & 
Sarkar, 2013). 
 Despite the known phenotypic changes in APP-/- mice, the physiologic 
function(s) of APP is less certain. However, over the last three decades 
numerous studies have investigated the APP family and much is now known. 
The structures of APP, APLP1 and APLP2 are similar (U. C. Muller & Zheng, 
2012). All three proteins are membrane spanning with a small intracellular 
domain and a large n-terminal ectodomain. The mature proteins are processed 
similarly by proteases, resulting in the release of soluble extracellular domain 
APP/APLP fragments termed sAPP and sAPLPs (Walsh et al., 2007). Research 
on the APP family of proteins highlights their importance, particularly in the 
central nervous system. The APP family of proteins have been characterized as 
synaptic adhesion molecules and upregulated during synaptogenesis (Schilling 
et al., 2017). Furthermore, the full length APP protein itself is believed to be 
involved in certain signaling processes and may function as a cell surface 
receptor for extracellular ligands (Hass & Yankner, 2005). It has also been 
reported that APP and its metabolites play a role in neurite outgrowth and 
neuronal migration (Gakhar-Koppole et al., 2008). Taken together, these studies 
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suggest APP and its metabolites can influence a variety of cellular processes and 
may be particularly important in the CNS and at the synapse.  
 In our other work, we observed higher levels of insulin degrading enzyme 
(IDE) protein in pancreatic tissue derived from APP-/- animals compared to 
control animals (Kulas, Puig, & Combs, 2017). IDE is a zinc metalloprotease 
widely recognized for its role in hydrolyzing insulin in addition to numerous other 
substrates including the plaque forming peptides Aβ and pancreatic amylin or 
IAPP (Kurochkin et al., 2018). In this study we sought to expand on this 
observation and have examined the APP-/- mice to test the hypothesis that 
deletion of the APP gene alters the protein levels of IDE. 
IDE Protein and mRNA are Increased in APP-/- Tissues 
 We began examining the role of APP in regulating IDE by collecting liver 
tissue from two month old female C57BL/6 and APP-/- mice. This tissue was 
chosen in particular because of the physiologic importance of insulin signaling in 
regulating liver gluconeogenesis and glycogenolysis. The transgenic APP 
knockout mouse has the APP gene knocked out in all tissues via deletion of the 
promoter region and first exon. Mouse liver was homogenized on ice and protein 
content was assessed by western blot. (Fig 15A). Interestingly, IDE protein levels 
were found to be significantly increased in APP-/- muscle (n=7, P<0.023) 
compared to controls. Next, we examined muscle tissue collected from WT and 
APP-/- animals (Fig 15B). Like in liver, we observed increased IDE protein 
content in liver tissue 
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Figure 15.  IDE is increased in APP-/- tissues.  
(A-C) IDE protein was measured in liver (n=7), gastrocnemius 
muscle (n=6) and hippocampus tissue (n=6-7) by western blot and 
normalized to GAPDH as a loading control.  
 
(D) IDE mRNA levels were measured in hippocampus extracts 
(n=4-5) and normalized to ribosomal 16S RNA as a loading control. 
Statistical significance p<0.05* was determined by students t-test.  
 
(E) Immunohistochemistry for IDE protein was performed on WT 
and APP-/- brain tissue sections (n=4-6). Data is graphed as ± 
SEM. 
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extracts from APP-/- mice compared to WT controls (n=7, p=0.001). These data, 
along with our previous observations of elevated IDE protein in pancreatic 
extracts from APP-/- mice, suggested to us that APP negatively regulates IDE 
levels in numerous peripheral tissues. 
 It has been suggested that IDE degrades a number of small 
amyloidogenic peptides, including Aβ, which may in turn have important 
implications in the pathogenesis of Alzheimer’s Disease. Because of this 
seemingly important role of IDE in peptide clearance, we next sought to examine 
if ablation of the APP gene altered IDE protein levels in the CNS. Because the 
hippocampus serves a critical role in memory and is damaged early in the 
progression of AD, we collected hippocampus tissue from WT and APP-/- brain 
hemispheres and extracted protein for western blot (n=6-7). As expected, APP 
was not detectable in APP-/- brain tissue homogenate (Fig 15C).  Surprisingly, 
IDE protein levels were found to be significantly increased and almost three fold 
higher in APP-/- hippocampus tissues compared to WT controls (p<0.001). This 
suggested that APP regulation of IDE extends to the central nervous system. We 
then examined mRNA levels to determine if APP is regulating IDE at the level of 
transcription or if it is a post-translational phenomenon. RNA was extracted from 
WT and APP-/- hippocampus tissues and converted to cDNA and the relative 
abundance of IDE transcripts were determined relative to 18s ribosomal RNA 
(n=4/5). Interestingly, we observed a significantly increased abundance of IDE 
mRNA in APP-/- hippocampus tissue compared to WT controls (p=0.002)  
(Fig 15D). Similar to protein levels of IDE, we observed a greater than 3 fold 
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average increase in IDE expression in APP-/- hippocampus tissue compared to 
WT controls. To gain a greater understanding of which cell types may be most 
abundantly expressing IDE, we performed immunohistochemistry to detect IDE in 
WT and APP-/- brain tissue. IDE was detectable throughout the brain including in 
white matter. Neurons within the hippocampus were stained to a greater extent 
than other cell types, though IDE immunostaining did not robustly label a single 
cell type compared to others in the CNS (Fig 15E). Collectively these data 
suggested that APP acts as a negative regulator of IDE levels and that ablation 
of APP increases IDE at the level of transcription. IDE is produced throughout the 
brain and across many cell types. 
IDE Protein is Increased in APP-/- Neuron, Astrocyte  
and Microglia Cell Cultures. siRNA Knockdown of APP  
in Microglia Increases IDE.  
 
 Following our observation that IDE mRNA and protein levels are robustly 
increased in the hippocampus tissue of APP-/- mice, we next sought to 
determine which cell type(s) found in the brain are responsible for increased IDE 
content. We began by culturing embryonic day 16 neurons from WT and APP-/- 
mouse embryos (Fig 16A). As expected, APP was abundant in WT neurons and 
not detectable in APP-/- cultures. Consistent with our observations in whole 
tissues, IDE protein levels were significantly increased in APP-/- neuronal 
cultures compared to WT controls (n=4, p<0.010). Unlike neurons, astrocytes 
and microglia, two other abundant cell types found in the CNS, produce a higher 
molecular weight isoform of APP which may have functional consequences for 
APP biology. Astrocytes are the most abundant cell type found in the CNS and 
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Figure 16.  IDE is increased in APP-/- cell cultures.  
 
(A-C) Primary cell cultures of neurons (n=4), astrocytes (n=3), and 
microglia from WT, APP-/- and the APP/PS1 mouse model of AD 
were grown and assessed for IDE protein content by western blot 
with GAPDH as a loading control. Significance p<0.05* was 
determined by students t-test.  
 
(D) Cultures of SIM-A9 mouse microglia cells (n=6/condition) were 
treated with either scrambled siRNA or anti-APP siRNA for one 
week. After treatment, total cell protein content was assessed by 
western blot with α-tubulin as a loading control. Significance 
p<0.05* was determined by students t-test. Data is graphed as ± 
SEM. 
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play an important role in brain metabolism among many other functions. Thus, 
we cultured astrocytes and microglia to examine if APP regulates IDE protein in 
these glial cell types in a manner similar to neurons (n=3/condition). We 
observed that APP migrated at higher molecular weight in astrocytes relative to 
neurons, consistent with known higher molecular weight isoforms of APP in these 
cells (Figure 16B). IDE protein levels were found to be significantly increased in 
both astrocyte (p=0.009) and microglia (Figure 16C, p=0.009) cultures relative to 
WT controls. This data suggested APP regulates IDE in both neuron and glia and 
that APP regulation of IDE is not specific to the isoform of APP expressed in 
diverse cell types. Furthermore, this suggests that multiple cell types are 
responsible for increased total IDE levels found in APP-/- hippocampus extracts.  
 Given that we observed increased IDE in APP-/- microglia, and that 
microglial IDE may be particularly important for degrading Aβ, we next tested the 
hypothesis that knockdown of APP with siRNA in the SIMA9 microglial cell line 
will increase IDE levels in vitro (Figure 16D). Knockdown of APP protein was 
performed over 1 week with either an anti-APP siRNA pool or a scrambled siRNA 
control (n=6/condition). As expected, treatment with anti-APP siRNA significantly 
reduced APP as measured by western blot. (p=0.003). Surprisingly, IDE protein 
levels were robustly and significantly increased in microglia (p<0.001) treated 
with anti-APP siRNA, suggesting that knockdown of APP in vitro is sufficient to 
increase IDE protein levels in cultured cells. This also suggests that APP has a 
direct role in regulating IDE and the increased levels of IDE observed in the  
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APP-/- mouse may not be a consequence of general differences in the 
physiology of the animals. 
IDE Activity is Increased in APP-/- Tissues 
 While numerous APP-/- mice tissues had increased IDE content 
compared to WT controls, we next examined if the enzymatic activity of IDE was 
also increased in APP-/- mouse tissues. To measure IDE activity, we utilized a 
commercially available IDE activity assay. This assay utilizes a FRET peptide 
IDE substrate that emits increased 5-FAM fluorescence when hydrolyzed by the 
IDE enzyme. Hippocampus tissue, gastrocnemius muscle and liver tissue were 
collected from 2 month old WT and APP-/- mice (n=6 condition) and 
homogenized. Each tissue homogenate was then mixed with the IDE substrate 
and fluorescence was measured over time (Fig 17). The IDE activity of each 
tissue extract was calculated and normalized to the total protein content of the 
sample. Significantly increased IDE activity was observed in APP-/- hippocampus 
(p=0.016) and liver extracts (p=0.003), indicating that increased IDE protein 
content in these tissues leads to functional differences in IDE activity. Unlike 
hippocampus and liver tissue, no significant differences in IDE activity were 
observed between WT and APP-/- gastrocnemius muscle tissue extracts. 
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Figure 17.  IDE activity is increased in APP-/- tissues. WT and APP-/- tissues 
(n=6) were harvested on ice and rapidly assayed for IDE activity 
over the course of 1 hour. The IDE activity assay uses a FRET 
peptide which is liberated from a quencher and exhibits increased 
fluorescence when cleaved by IDE. Relative fluorescent units are 
converted to concentrations of FAM via standard curve. The data is 
normalized to the amount of total protein collected from each 
tissue. IDE activity was calculated from each animal tissue and 
significance p<0.05* was determined by students t-test. Data is 
graphed as ± SEM. 
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Insulin Content and Insulin Signaling are Altered in  
APP-/- Hippocampus tissue and Synaptosomes 
 
 We next sought to probe for consequences of increased IDE protein 
content and enzyme activity on insulin levels and insulin signaling markers in 
hippocampus tissue. We measured the insulin content of 2 month old WT and 
APP-/- hippocampus extracts by ELISA (n=11/13) and normalized to total protein 
(Fig 18A). Hippocampus extracts from APP-/- mouse had significantly reduced 
hippocampal insulin content compared to WT animals (p=0.032), suggesting that 
insulin content of the brain may be reduced in these animals. Following this 
observation, we next examined hippocampus extracts from WT and APP-/- mice 
for changes in insulin signaling markers. While we were unable to clearly detect 
phosphorylated insulin receptor in these lysates (Fig 18B), we also examined 
markers of insulin signaling downstream of the receptor which serve as a positive 
indicator of insulin signaling. We observed significantly reduced (p=0.025) levels 
of pAKT S308 in APP-/- hippocampal lysates compared to WT controls, 
suggesting that APP-/- animals have diminished or impaired insulin signaling in 
brain tissue. 
 To further examine insulin signaling in the brains of these animals, we 
prepared synaptosomes from WT and APP-/- tissues and stimulated them 
acutely with insulin ex vivo. Stimulated synaptosome lysate was then analyzed 
for protein and phosphor protein content by WES capillary western blot. We have 
previously utilized this method to examine insulin signaling in the brains of other 
transgenic mice (Puig et al., 2016) and the details of this method have been 
 76 
Figure 18.  Insulin signaling and content are altered in the APP-/- brain.  
 
(A) Total hippocampal insulin content was measured in RIPA 
extractions of WT and APP-/- hippocampus tissue by ELISA. (n=13) 
 
(B) Insulin signaling cascade markers were assessed in two-month 
old WT and APP-/- hippocampal tissue. (n=5-6/condition)  
 
(C) Hippocampal synaptosomes from 2 month old WT and APP-/- 
animals were prepared and stimulated with 10 nM insulin (n=5/5) or 
200 nM insulin (n=6/4) pIR, total IR and β tubulin protein levels 
were measured using the WES system. Data was collected using 
the area under peaks for the specified proteins and analysis 
performed using a Student’s t-test with significance p<0.05*.  
 
Data is graphed as ± SEM. 
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expanded on in recent literature (Franklin & Taglialatela, 2016). WT and APP-/- 
synaptosomes were stimulated with either 10 or 200 nM insulin (n=4-6/condition). 
Interestingly, APP-/- synaptosomes showed diminished phosphorylation of the 
insulin receptor compared to WT synaptosomes when stimulated with either 10 
nM (p=0.0315) or 200 nM (p=0.0265) insulin. (Fig 18C). No differences in the 
ratio of phosphorylated IR to IR were observed in the unstimulated 
synaptosomes. These data suggest that APP-/- animals have impaired insulin 
signaling in the brain at the level of the insulin receptor. 
Aged APP-/- Mice Display Fasting Hypoglycemia  
Without Changes in Glucose Tolerance. 
 
 While our data suggests APP-/- animals have changes in brain insulin 
signaling, the potential effects of elevated peripheral IDE on metabolic 
homeostasis remains uncertain. To determine if APP-/- animals have abnormal 
glucose homeostasis we performed glucose tolerance testing on 12 month WT 
and APP-/- (n=11-13/condition). Animals were fasted for 5 hours on the day of 
the experiment and then administered 2g/kg body weight glucose by 
intraperitoneal injection. Blood glucose was monitored by glucometer just prior to 
injection and at 15, 30, 60 and 120 minutes after injection. Data was graphed as 
blood glucose versus time and the area under the curve was assessed (Fig 19). 
No significant difference was observed in overall glucose tolerance (p=0.12) 
between WT and APP-/- animals. However, we did observe a robust and 
significant reduction in the fasting blood glucose levels of APP-/- animals 
(p=0.002) compared to WT controls. Blood glucose was also measured in free 
fed WT and APP-/- mice (n=5/condition) and was not significantly different 
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(p=0.221). These data suggest APP-/- animals are glucose tolerant but have 
metabolic abnormalities when fasted.  
 
 
 
Figure 19.  Aged APP-/- animals show metabolic changes. WT and APP-/- 
animals (n=11-13) were fasted and subjected to glucose tolerance 
testing with IP injections glucose. Area under the curve (AUC) was 
measured for each animal’s blood glucose over time, and WT and 
APP-/- animals were compared by t-test with p<0.05*. Blood 
glucose was measured and graphed in fasted or in free fed (n=5) 
WT and APP-/- mice. Significance p<0.05* was determined by 
students t-test. Data is graphed as ± SEM. 
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Overexpression of APP or Treatment with Secretase  
Inhibitors Does Not Alter IDE Levels.  
 
 APP is cleaved by a variety of enzymes termed secretases which result in 
the production of various APP fragments. To examine if inhibition of secretases 
through selective inhibitors is sufficient to alter levels of IDE, SIMA9 microglia 
cells were treated for 7 days in 1% serum solution with the alpha secretase 
inhibitor GI254023X, the beta secretase inhibitor Verubecestat, or the gamma 
secretase inhibitor DAPT (Fig 20A). No significant difference was found in the 
IDE protein content of SIMA9 cells treated with inhibitors compared to untreated 
or vehicle controls (n=3/treatment, p=0.45) by one-way ANOVA. 
 Next, to further examine if an APP metabolite may be capable of changing 
IDE levels, we tested if the application of recombinant sAPP fragments to APP-/- 
astrocyte primary cultures would reduce the protein levels of IDE. Cells were 
treated for 3 days with 20 nM of bacterial derived recombinant sAPPα, sAPPβ or 
mutant sAPPa, or with 200 nM eukaryotic derived sAPPα695 or sAPPα751 (Fig 
20B). These sAPP fragments did not alter IDE levels in cultures, further 
suggesting the full length APP protein or another APP fragment may be 
upstream of changes in IDE levels observed in APP-/- tissues. 
 Finally, we tested if overexpression of the APP695 isoform or the APP751 
isoform in APP-/- astrocytes is sufficient to reduce levels of IDE (Fig 20C). 
Primary astrocyte cultures were transfected using lipofectamine with plamsids 
coding for APP695, APP751, Green fluorescent protein (GFP), or mock 
transfected as a control. Cellular protein was collected after 5 days and IDE was 
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Figure 20.  APP fragments and secretase inhibitors do not alter IDE. 
Overexpression of APP does not alter IDE levels in APP-/- cells.  
(A) SIMA9 microglia (n=3/condition) were treated with secretase 
inhibitors, DMSO vehicle, or left untreated for one week and IDE 
protein content was measured. Significance p<0.05* was 
determined by one-way ANOVA.  
(B) APP-/- primary astrocyte cultures (n=4/condition) were treated 
with bacterial recombinant sAPPα, sAPPβ, mutant n-terminal 
truncated sAPPα or euaryotic derived sAPPα695 and 751. IDE 
protein was measured and significance p<0.05* was determined by 
one-way ANOVA.  
(C) APP-/- astrocyte primary cultures (n=6/condition) were 
transfected with APP695, APP751 or GFP plasmids or mock 
transfected. IDE protein was measured and significance p<0.05* 
was determined by one-way ANOVA.  
Data is graphed as ± SEM. 
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measured by western blot. Surprisingly, overexpression of APP in APP-/- 
astrocytes did not significantly change IDE levels (p=0.56) (Fig 20C). This 
suggests that overexpression of APP may not be capable of restoring the normal 
functions of APP, possibly due to aberrant processing of the transgene protein 
product. Alternatively, overexpression of APP may not allow for normal protein-
protein interactions of the APP proteins, or that overexpressed APP may not be 
trafficked appropriately to perform its normal functions within the cell. 
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CHAPTER V 
DISCUSSION 
Study 1 - Amyloid Precursor Protein  
in the Endocrine Pancreas 
 
 In this study we report the presence of APP in pancreatic tissue, including 
the detection of APP within insulin producing pancreatic β cells. We have 
confirmed the presence of pancreatic islet APP expression in both C57B6 mice 
and human samples, demonstrating this pattern of APP expression is confirmed 
across species. Interestingly, we observed APP is overexpressed within the 
pancreatic islets of the APP/PS1 mouse model of AD. This mouse model of AD 
uses the mouse prion promoter to drive human APP transgene expression. This 
finding indicates that the prion promoter itself may be a useful tool for driving 
robust gene expression of target genes specifically within the endocrine 
compartment of the pancreas. It has recently been reported that a 3xTg-AD 
model of Alzheimer’s disease, which uses Thy 1.2 promoter, also overexpresses 
human APP within pancreatic islets (Vandal et al., 2015). Because of the 
similarity in gene expression and phenotype between pancreatic islets and 
neurons, it is likely that numerous genetic elements which drive high expression 
of genes in the central nervous system will also result in robust gene expression 
in pancreatic islets (Atouf, Czernichow, & Scharfmann, 1997; Martens et al., 
2011; Moller et al., 1992).
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 Despite the robust overexpression of human mutant APP within the 
pancreatic islets of the APP/PS1 mouse, we were unable to detect the presence 
of monomeric human Aβ, Aβ oligomers, or fibrils within APP/PS1 pancreatic 
tissue or islet cultures by ELISA or immunohistochemistry. This is in agreement 
with previous reports suggesting β-secretase activity is not present in pancreatic 
tissue extractions despite the presence of BACE1 RNA (Ehehalt et al., 2002; 
Mowrer & Wolfe, 2008; Sinha et al., 1999). In 2002, Ehehalt et al. described a 
shorter isoform of BACE1 RNA termed BACE1C in the pancreas along with the 
more well-known BACE1A isoform. BACE1C lacked detectable β-secretase 
activity in their assays, suggesting that pancreatic tissue may not produce Aβ, in 
part, because of the presence of this enzymatically inactive splice variant. 
However, BACE1A is still the dominant isoform of BACE1 found in the pancreas 
so alternative splicing cannot be the sole reason for this phenomenon. In 2008, 
Mowrer and Wolfe described similar alternative splicing of BACE1 in the 
pancreas relative to the brain, but also noted that this alone was not sufficient to 
explain the lack of BACE1 activity in pancreatic tissue. These authors postulated 
that pancreatic BACE1 is inactive due to post-translational processing 
mechanisms. Indeed, it has been shown that BACE1 in the pancreas and other 
tissues undergoes differential proteolytic processing compared to the brain 
resulting in lower or undetectable levels of the BACE1 holoprotein (Huse et al., 
2003). Instead of β-secretase mediated APP processing, our data suggests that 
APP in pancreatic islets is processed by α-secretase activity to release sAPPα. 
This is clearly in contrast to the CNS where both forms of APP processing occur. 
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We were also unable to detect plaque deposition in human pancreas sections 
using the anti-Aβ antibody, 4G8. It is possible that pancreatic islets could be 
affected by circulating concentrations of Aβ rather than locally produced Aβ.  
 To study the significance of APP in pancreatic islet function, we examined 
two month old WT, APP-/-, and APP/PS1 animals for differences in glucose 
tolerance by oral gavage. This time point was important for assessing the role of 
islet APP in glucose tolerance because it is well before Aβ deposits are known to 
form in the CNS of the APP/PS1 mouse. Aβ oligomers or over-overexpression of 
the Aβ producing enzyme BACE1 in the brain have recently been demonstrated 
as sufficient to induce peripheral metabolic dysregulation (J. R. Clarke et al., 
2015; Plucinska et al., 2016).  We detected no significant differences in glucose 
tolerance across strain, indicating ablation or overexpression of mutant APP 
does not severely compromise glucose homeostasis mechanisms or severely 
impair islet function at two months of age. Multiple organ systems such as liver 
and kidney gluconeogenesis and muscle glucose uptake are involved in glucose 
homeostasis, thus the effect of overexpression or ablation of pancreatic islet APP 
on blood glucose levels during glucose tolerance testing may be masked by 
glucose-regulating compensatory mechanisms in other organs. In addition to 
glucose tolerance testing, we also measured the pancreatic insulin and glucagon 
content by ELISA. Our results indicate that while total insulin content was 
unchanged, total pancreatic glucagon levels and glucagon immunostaining were 
significantly attenuated in animals expressing the APP/PS1 transgenes, 
suggesting that overexpression of mutant APP or presenilin in pancreatic islets 
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may alter the development of α cells or affect their secretory functions. BACE2 
levels were also diminished in the APP/PS1 animals, further suggesting that the 
APP/PS1 mice may have fewer pancreatic α cells. Future work requiring, 
perhaps stereologic assessment, may provide a clearer indication of changes in 
total α cell numbers in the APP/PS1 compared to WT mice. One possible 
mechanism for a change in α cell number could be through alterations in Notch 
biology. Presenilin is part of the γ–secretase complex which cleaves the Notch 
protein to liberate the biologically active NICD fragment. NICD then enters the 
nucleus where it affects transcription(Chan & Jan, 1999). Notch signaling is 
thought to play a critical role in the normal development of the endocrine 
pancreas suggesting that mutant presenilin expression in the pancreas may 
indeed influence this biology (Hald et al., 2003; Jensen et al., 2000; Murtaugh, 
Stanger, Kwan, & Melton, 2003). 
 Our examinations of pancreatic protein content in two month old animals 
revealed changes in the levels of IDE, GLUT4 and BACE2.  Animals lacking the 
APP gene showed increased levels of IDE and GLUT4, while APP-/- and 
APP/PS1 animals showed reduced BACE2 levels compared to wild type in 
western blot. IDE has been identified as an enzyme capable of degrading Aβ and 
amylin in addition to insulin. These functions may be important in the pancreas, 
as inhibition of IDE has been shown to enhance toxicity of islet amylin (R. G. 
Bennett, Hamel, & Duckworth, 2003). GLUT4 is considered the insulin 
responsive glucose transporter and is well known for its role in muscle and fat 
tissue. Recent studies have presented evidence that both sAPP and Aβ may 
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influence the cellular localization of GLUT4 (Hamilton et al., 2014; Oliveira et al., 
2015).  BACE2 has been previously implicated as both an APP cleaving enzyme 
and regulator of β cell function through the cleavage of the transmembrane 
protein TMEM27 (Esterhazy et al., 2011). It has been proposed that full length 
TMEM27 supports beta cell growth and insulin secretion, thus blocking its 
cleavage by inhibiting BACE2 activity may represent a therapeutic strategy to 
control blood glucose in diabetic patients (Southan, 2013).  
 We also examined protein content of primary islet cultures from 12 month 
old WT, APP-/-, and APP/PS1 animals. Similar to whole-pancreas extracts, IDE 
was present at higher levels in APP-/- compared to WT controls. This indicates 
that APP may play a role in negatively regulating the expression of IDE, or that 
differences in the APP-/- animals lead to upregulated IDE expression. We could 
not detect GLUT4 in our islet lysates, however GLUT4 is not considered a major 
glucose transporter in the pancreatic endocrine cells and differences observed in 
whole pancreas were likely from other cell types. BACE2 levels were not 
significantly different in islets from transgenic animals compared to controls, 
which is in contrast to both our immunohistochemistry and whole pancreas 
western blot results. This could be in part due to the process of pancreatic islet 
isolation in which the pancreas is digested with proteases to liberate the islets 
from exocrine tissue. It is likely that this isolation process would affect the cells at 
the islet periphery expressing BACE2. Alternatively some BACE2 in whole 
pancreatic extracts may be due to the contribution of other cell types.  
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 Although higher glucose culture concentrations are reported to improve 
islet culture and reduce apoptosis, we chose to avoid high glucose levels that 
may influence APP expression or processing. Several lines of evidence suggest 
that culturing cells in high glucose concentrations can alter APP processing and 
affect APP protein levels (H. J. Lee et al., 2016; Yang, Wu, Zhang, & Song, 
2013). Additionally, a recent study utilizing glucose clamps to sustain 
hyperglycemia demonstrates that increasing glucose concentrations in vivo alters 
APP processing to influence Aβ levels in the CSF (Macauley et al., 2015). We 
considered the implications of these studies and thus 5mM glucose was selected 
for our paradigm. We avoided larger islets with necrotic centers in an attempt to 
minimize artifacts induced by cell death from lower glucose concentrations. 
However, since islet glucose concentration exposure in vivo may be well above 
5mM, there was a concern that our primary islet sAPPα stimulation paradigm 
was superimposed upon a glucose deficient condition. To verify that sAPPα 
stimulated insulin secretion at higher glucose concentrations, we employed the 
MIN6 cell line to demonstrate that insulin secretion was still potentiated at 
16.7 mM glucose concentration. Future studies will require further optimization of 
islet culture conditions including higher glucose concentrations. In addition, it is 
important to remember that although the wild type mice are littermate controls of 
the APP/PS1 mice in our study, the APP-/- mice were derived from a 
homozygous colony and comparison to the other two lines is potentially limited 
by this.  Nevertheless, these data suggest changes in pancreatic APP content or 
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processing may result in alterations in the levels of proteins important to 
pancreatic physiology and influence the pathology of pancreatic diseases. 
 Interestingly, our immunohistochemistry data indicated that primary 
antibodies directed against BACE2 showed increased binding in pancreatic α 
cells compared to β cells in both mouse and human tissue. This is particularly 
interesting as BACE inhibitors are actively being explored as a therapeutic 
strategy in AD (Kennedy et al., 2016). Our detection of BACE2 in α cells is in 
contrast to reports indicating the highest pancreatic BACE2 expression is found 
within pancreatic β cells (Esterhazy et al., 2011; Finzi et al., 2008). A likely 
reason for this discrepancy is the binding site of the antibody used to detect 
pancreatic BACE2. BACE1 and BACE2 share a high degree of sequence 
similarity, and several alternatively spliced transcripts of BACE1 are known to be 
present in the pancreas (Ehehalt et al., 2002; Mowrer & Wolfe, 2008). In 
agreement with our findings, a recent study by Segerstolpe et al. also observed 
higher expression of BACE2 in α cells relative to β cells through single cell 
transcription profiling (Segerstolpe et al., 2016). In this study we utilized a 
polyclonal antibody raised against the BACE2 pro-domain sequence not present 
in the BACE1 sequence. Pro-domain cleavage is thought to be an essential step 
in the activation of the BACE2 proenzyme, thus our immunohistochemistry 
results could indicate differences in BACE2 activation in α and β cells (Hussain, 
Christie, Schneider, Moore, & Dingwall, 2001; Hussain et al., 2000). 
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 Our assessments of isolated pancreatic islets demonstrate both 
endogenous murine APP and transgenic human APP are released as sAPP into 
culture media from WT and APP/PS1 mouse islets respectively. We also 
observed modest but significant differences in the insulin secretion properties of 
islets overexpressing or lacking APP compared to WT controls, suggesting the 
presence of APP may influence the basic functional properties of β cells in vitro. 
However, a lack of detectable differences in APP-/- and APP/PS1 animals 
compared to WT controls in glucose tolerance testing at two months of age 
suggests APP is not essential for normal islet insulin secretion or glucose 
homeostasis in vivo. 
 sAPP has been shown to exert effects on a variety of cell types. In the 
central nervous system, sAPP is thought to promote neurite outgrowth and 
influence the differentiation of neural stem cells (Baratchi, Evans, Tate, Abraham, 
& Connor, 2012; Freude, Penjwini, Davis, LaFerla, & Blurton-Jones, 2011; Jin et 
al., 1994; Porayette et al., 2009).  sAPP has also been implicated as having 
growth enhancing effect in pancreatic cancer, in addition to altering the 
proliferation rate of other cell types (Demars, Bartholomew, Strakova, & Lazarov, 
2011; Hansel et al., 2003; Woods & Padmanabhan, 2013). Our data indicate that 
recombinant sAPPα modestly potentiates insulin secretion in pancreatic islets 
from both mice and humans in vitro. This suggests that sAPP may exert effects 
on β cell function, potentially by acting on cell surface receptors in an autocrine 
fashion. The mechanism through which sAPP exerts its biological effects is 
uncertain and may be due to interactions with several proteins. Several studies 
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have identified putative cell surface receptors for sAPP. These include the P75 
neurotrophic receptor, LRP1, as well as APP itself (Hasebe et al., 2013; Kounnas 
et al., 1995). The putative receptors and biological effects of sAPP signaling have 
recently been extensively reviewed (Habib, Sawmiller, & Tan, 2016). Stimulation 
of these cell surface receptors by sAPP may influence the survival or phenotype 
of islets in culture. Indeed, recombinant sAPP has been shown to induce cell 
signaling cascades which may account for its effects on cultured islets (Bodles & 
Barger, 2005; Deng et al., 2015; Jimenez et al., 2011). Our future work will focus 
on identifying signaling cascades and downstream effects induced in pancreatic 
endocrine cells by both APP and sAPP. 
To our knowledge, our study is the first report showing sAPP is released 
from both primary mouse and human islet cultures into culture media. We also 
present new data indicating expression of the BACE2 protein in pancreatic α 
cells. Findings from this study contribute to the basic understanding of amyloid 
precursor protein and pancreatic islet physiology. 
Study 2 - Amyloid Precursor Protein  
and Insulin Degrading Enzyme 
 
 Glucose hypometabolism in the brain is a known component of advanced 
Alzheimer’s disease and is also observed in animal models of AD and in Down 
syndrome patients (Lao et al., 2018; Oh, Madison, Baker, Rabinovici, & Jagust, 
2016; Parent et al., 2017). Type 2 diabetes is also among the risk factors for the 
development of AD (Wijesekara, Goncalves da Silva, De Felice, & Fraser, 2017). 
Interestingly, growing research indicates that a normal physiologic function of 
APP and its associated fragments are regulators metabolic homeostasis. APP-/- 
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knockout mice, in addition to having lower body weight, show reduced weight 
gain when placed on a high fat diet (Puig et al., 2017). In muscle tissue, sAPPα 
has been shown to potentiate glucose uptake (Hamilton et al., 2014). APP’s role 
in metabolism may also be conserved across species. APL-1, the C. elegans 
homologue of APP, is both essential for survival and may play an important role 
in insulin homeostasis and metabolism (Ewald, Cheng, et al., 2012; Ewald & Li, 
2012; Ewald, Raps, & Li, 2012; Puig et al., 2017). Our data presented in this 
study indicates that ablation of the APP gene in mice or prolonged knockdown of 
the APP gene in cell culture results in increased levels of the insulin degrading 
enzyme (IDE) and changes in insulin signaling compared to controls. Increased 
IDE protein levels were found to be present in muscle, liver and in hippocampal 
tissue extracts from APP-/- animals. In agreement with this finding, primary cell 
cultures of neurons, astrocytes and microglia from APP-/- mice were all found to 
have higher IDE content than WT control primary cultures. Furthermore, mRNA 
levels of IDE were found to be significantly increased in hippocampal tissue 
extracts from APP-/- animals compared to controls, suggesting that increased 
IDE protein is the result of increased transcription of the IDE gene. The 
phenomenon of increased IDE was most robust in brain tissue and neurons 
relative to other tissues and cell types assessed in this study, which is interesting 
because APP, although expressed ubiquitously, is known to be particularly 
abundant in neuronal cells and generally abundant in the CNS. In further support 
of this observation treatment of SIMA9 microglial cells with anti-APP siRNA for 
one week was sufficient to increase protein levels of IDE. This suggests that loss 
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of APP directly mediates this effect, and it is not a consequence of broad 
changes in APP-/- animal development and metabolism. 
 To determine if increased levels of IDE protein resulted in functional 
differences in enzyme activity, we measured the activity of IDE in liver, muscle 
and brain tissue. In agreement with our western blot data, we observed robust 
and significantly increased IDE activity in both hippocampus and liver extracts 
from APP-/- animals compared to WT controls. IDE activity was surprisingly not 
statistically different in skeletal muscle tissue extracts, despite increased total 
IDE proteins levels. The lack of difference in muscle could be due to the nature of 
the activity assay, which uses cleavage of a FRET peptide as an indicator of IDE 
activity. It is possible that muscle tissue contains other enzymes capable of 
cleaving the FRET substrate, or that our protocol of homogenization was not 
sufficiently rigorous to liberate all of the IDE from the gastrocnemius muscle 
tissue. Alternatively, we observed additional lower molecular weight bands on 
western blots for IDE from muscle tissue lysates not present in other tissues, 
suggesting a there may be alternative forms of IDE in muscle compared to other 
tissues. 
 The ability of an enzyme present in tissue extracts to degrade insulin has 
been known for decades, and an insulin degrading enzyme was purified and 
further characterized by Duckworth et al. in 1972 (Duckworth, Heinemann, & 
Kitabchi, 1972; Mirsky & Broh-Kahn, 1949). In 1988, the IDE was cloned and 
definitively identified (Affholter, Fried, & Roth, 1988). While the brain was 
traditionally viewed as an insulin insensitive organ, increasing literature 
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demonstrates insulin and insulin signaling are involved in the normal physiology 
of the brain (Fernandez et al., 2017; Garcia-Caceres et al., 2016; Kleinridders et 
al., 2014). Moreover, evidence suggests that impaired insulin signaling may play 
a role in the pathology of AD (Ribe & Lovestone, 2016; Talbot et al., 2012).  
Intranasal insulin is currently under investigation as a therapeutic intervention for 
AD (Chapman, Schioth, Grillo, & Benedict, 2017). To determine if increased IDE 
in brain tissue results in lower levels of tissue insulin content we measured the 
total insulin content in lysates from WT and APP-/- hippocampal extracts by 
ELISA. We observed significantly reduced insulin levels in the hippocampus of 
APP-/- animals, suggesting that increased IDE activity in these animals may 
indeed lower tissue insulin content or increase insulin catabolism in 
homogenates. This is in general agreement with previous research showing IDE-
/- mice have impaired tissue insulin degradation (Farris et al., 2003). 
 Our data indicates that increased IDE protein and activity alter brain 
insulin signaling. We examined hippocampus protein extracts for markers of 
insulin signaling. While we could not clearly detect phosphorylated insulin 
receptor in our hippocampus homogenates, likely due to the transient nature of 
insulin receptor phosphorylation, we did observe modest but significantly reduced 
levels of pAKT(T308) in APP-/- hippocampal lysates compared to WT controls. 
This indicated that insulin signaling may be impaired or altered in APP-/- brain 
tissues. To further examine this possibility, we prepared synaptosomes from WT 
and APP-/- hippocampal tissues and stimulated them acutely using 10 nM or 
200 nM of insulin. At both concentrations of insulin tested, we observed 
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diminished phosphorylation of the insulin receptor in APP-/- synaptosomes 
compared to WT controls. This finding further indicates either loss of APP or 
increased IDE may in turn impair insulin signaling in the brain and this may be 
particularly robust at the level of the synapse. 
 To examine potential functional consequences of increased tissue levels 
of IDE in APP-/- animals, we performed glucose tolerance testing in 12 month old 
male and female WT and APP-/- animals. Pharmacological inhibition of the IDE 
in vivo has been shown to alter insulin levels and affect glucose tolerance 
(Deprez-Poulain et al., 2015). While we did not observe a significant difference in 
overall glucose tolerance between WT and APP-/- animals, we were surprised to 
observe that when aged APP-/- animals were fasted they became hypoglycemic. 
This is in contrast to our prior analysis of glucose levels in 2 month APP-/- 
animals, which did not reveal this phenomenon despite increased levels of 
pancreatic IDE (Kulas et al., 2017). This finding is, however, is in general 
agreement with work by Needham et al. which demonstrated lower plasma 
glucose in both APP-/- and APLP2-/- mice (Needham et al., 2008).  Other groups 
have shown that aged APP-/- animals have impaired spatial learning in advanced 
age (U. Muller et al., 1994; Phinney et al., 1999). It can be speculated that aging 
may reveal phenotypes in present in APP-/- mice not observed at earlier ages. 
Furthermore, this compromised metabolic homeostasis may reveal the potentially 
deleterious consequences of increased IDE in tissues, in spite of normal overall 
glucose tolerance. IDE has been implicated in the degradation of the glucose 
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elevating hormone glucagon, which may account for this phenomenon in part 
(Shen, Joachimiak, Rosner, & Tang, 2006).  
 The mechanism by which ablation of APP results in increased IDE 
transcription remains to be elucidated. It has been demonstrated that the 
intracellular c-terminal fragment can interact with other proteins like Fe65 and the 
histone acetyltransferase Tip60 to effect transcription (Cao & Sudhof, 2001; 
Kimberly et al., 2001).  However, treatment of SIMA9 microglia with secretase 
inhibitors for one week was not sufficient to significantly change IDE levels in 
SIMA9 cells, potentially implicating full length APP or an alternative secretase as 
the primary mechanistic regulator upstream of changes in IDE. Previous 
research has indicated that APP may be able to affect transcription 
independently of γ-secretase activity (Hass & Yankner, 2005). Furthermore, in 
vitro treatment of APP-/- astrocytes with recombinant sAPPα or sAPPβ, or SIMA9 
cells with α and β secretase inhibitors did not alter IDE levels, further implication 
a mechanism involving the full length APP protein. In spite of this, 
overexpression of human APP695 and APP751 was not sufficient to change IDE 
levels in APP-/- astrocyte primary cultures. However, this may be due to 
abnormal processing or trafficking of overexpressed APP. It is also possible that 
overexpression results in failure of the endogenous signaling machinery present 
under WT conditions. Nonetheless, long-term siRNA knockdown of APP in vitro 
was sufficient to robustly change IDE levels in support of our observations in the 
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APP-/- mouse. It is possible that changes in IDE occur as an indirect effect of 
loss of APP instead of APP being directly involved in IDE transcription. 
 IDE has previously been linked to APP in that IDE is known to degrade 
both the Aβ and AICD peptide fragments of APP. In this study we present new 
evidence that ablation of APP is sufficient to increase IDE transcription, protein 
levels and activity both in the brain and in peripheral organs. These findings 
represent a new link connecting APP to metabolic homeostasis and expand on 
the already substantial number of links suggesting aberrant metabolic processes 
may play a critical role in Alzheimer’s Disease. 
Limitations of Work Presented in this Dissertation 
 The research presented in this dissertation indicates a role for APP in 
insulin homeostasis and animal metabolism. The limitations of the work 
discussed in this study are presented as follows. 
 Data presented in these studies primarily report on differences observed 
across various strains of mice. Each mouse strain in this study, while originally 
developed on a C57BL6 background, likely has unique attributes due to both 
inbreeding of animals and having different origins. It is well established that 
various behavioral, metabolic and biochemical differences occur across mouse 
strains (Avila, Kim, & Massett, 2017; Linder, 2006; Vaillant et al., 2014). Thus, 
differences in animal background may account for at least some of the metabolic 
and protein changes observed in APP-/- and APP/PS1 animal tissues. The role 
of sex as a factor of APP in influencing metabolic homeostasis was not rigorously 
examined in these studies, and most experiments here utilized female animals. 
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However, differences in IDE and fasting blood glucose reported here in APP-/- 
females were also observed in male mice. 
 sAPPα stimulation of pancreatic endocrine cells may not represent 
physiologic conditions. In this dissertation recombinant sAPPα was applied at 
concentrations of 10-20 nM. This concentration was chosen based on the known 
effects of sAPPα in stimulating signaling and neuroprotective effects in neurons 
(Jimenez et al., 2011). The true concentration of sAPP in the blood is likely 
different than this concentration. It has been shown that mice which express 
human sAPPα have concentrations of approximately 200 nM in plasma, while 
humans have been shown to have approximately 10-20 ng sAPPα/mg plasma 
protein (Bailey et al., 2012; Ray, Long, Sokol, & Lahiri, 2011). Moreover, the 
effect of recombinant sAPPα on cultures pancreatic islet insulin secretion was 
modest and no difference in glucose tolerance was detected across strain. This 
could indicate sAPP may only play a minor role in affecting islet function in vivo, 
or that its effects on islets involve biological parameters not measured in these 
studies.  
 Regarding the role of APP in regulating IDE, all experiments in this study 
utilized either mouse tissues or mouse-derived cell lines and primary cultures. 
Thus, APP regulation of IDE is not demonstrated to be conserved in humans 
here. The mechanism of APP regulation of IDE remains uncertain and may be 
due to downstream dysfunction following APP ablation, rather than APP directly 
mediating transcription of the gene.  Thus, the mechanistic relationship between 
APP and IDE awaits more investigation.
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Summary Conclusions and Future Directions 
 The work presented in this study suggests the APP protein plays a role in 
insulin homeostasis independent of its role in Aβ production (Summary Fig 21). 
APP and its metabolites are detectable in the pancreas, where they may 
influence pancreatic physiology and pancreatic insulin release. Furthermore, loss 
of APP increases IDE levels and activity, suggesting a role for APP in whole 
body insulin turnover and signaling. Ablation of APP in mice leads to broad 
metabolic changes including hypoglycemia which occur as a function of age and 
are revealed by fasting. 
 Future work to expand on these studies will examine APP in the Min6 cell 
line. We have begun to characterize APP in this pancreatic β cell line and 
observe similar processing and release of APP into conditioned media as 
observed in the primary pancreatic islet cultures presented in this dissertation. 
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Figure 21.  Model of Pancreatic APP and summarized findings.  
(A) Pancreatic α and β cell APP is processed through the α-
secretase pathway to yield sAPPα which is detected in pancreatic 
cell culture media. sAPPα exerts effects on cells, possibly by acting 
on cell surface proteins in an autocrine or paracrine manner to 
effect pancreatic β cell phenotype. Full length APP itself may serve 
as a receptor for sAPP or drive downstream events independently 
of sAPPα.  
(B) APP-/- mice show elevated IDE protein and activity in numerous 
tissues including the brain. These mice also display low 
hippocampal insulin content and impaired insulin signaling. APP-/- 
animals also show impaired glucose homeostasis when fasted. 
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